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ABSTRACT 
Aripiprazole is a unique antipsychotic drug with favourable therapeutic effects and 
improved extrapyramidal side-effects. Its partial agonism for the dopamine D2 receptors 
(D2R) is considered to contribute to the clinical effects of aripiprazole. However, how 
aripiprazole regulates D2R-mediated cellular signalling pathways, as well as their 
downstream substrates, is not clear. Therefore, this thesis investigated the cellular 
mechanisms of aripiprazole on these signalling pathways and regulators in an animal 
model, by comparing aripiprazole with a D2R antagonist – haloperidol and a D2R partial 
agonist – bifeprunox. 
 
The study in Chapter 3 investigated the acute effects of aripiprazole (a single injection) 
on the D2R downstream cyclic adenosine monophosphate (cAMP)-protein kinase A 
(PKA) and protein kinase B (Akt)-glycogen synthase kinase 3 beta (GSK3β) signalling 
pathways. Aripiprazole affected PKA-C expression similarly to haloperidol, but not 
bifeprunox, in the caudate putamen (CPu) and ventral tegmental area (VTA). In addition, 
aripiprazole increased phosphorylation of GSK3β in the prefrontal cortex (PFC), 
nucleus accumbens (NAc), CPu and substantia nigra (SN). Haloperidol also increased 
phosph-GSK3β in the NAc. These results suggest acute administration of aripiprazole 
affected the cAMP-PKA and Akt-GSK3β signalling pathways differentially from 
haloperidol and bifeprunox in various brain areas. It also indicated that its relatively low 
intrinsic activity for D2Rs might contribute to the effects of aripiprazole. 
 
The study in Chapter 4 continued to examine the effects of 1-week aripiprazole 
treatment by oral administration. In addition to PKA signalling, γ-aminobutyric acid 
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examined. The data have shown that 1-week administration of aripiprazole elevated 
PKA activity by increasing the phosphorylation levels of PKA in the NAc. Aripiprazole 
also increased the expression of the GABAA (β-1) receptor and CREB in the NAc. 
Furthermore, haloperidol elevated PKA activity in both the NAc and CPu, while 
haloperidol increased GABAA (β-1) receptor expression and CREB1 expression (not 
significantly) in the NAc. These findings suggest that aripiprazole might exert its 
clinical effects via the regulation of GABAA receptors and CREB1 in the NAc, possibly 
via the D2R-mediated PKA signalling pathway.  
 
In the study in Chapter 5, the effects of 1-week administration of aripiprazole on the 
Akt-GSK3β and Dvl-GSK3β-β-catenin signalling pathways were examined. The results 
demonstrated that aripiprazole increased GSK3β phosphorylation in the PFC, NAc and 
CPu, while haloperidol and bifeprunox had such effects only in the NAc and CPu, 
respectively. Additionally, both aripiprazole and haloperidol increased the expression of 
Dvl-3 and β-catenin in the NAc. The studies in Chapters 4 and 5 suggest that up-
regulation of GABAA (β-1) receptors and CREB1 in the NAc, and GSK3β 
phosphorylation in the PFC and NAc may be involved in the clinical effects of 
aripiprazole; they further indicate that the relatively low intrinsic activity for D2Rs 
might be associated with the actions of aripiprazole. 
 
In the clinic, in order to control symptoms of schizophrenia, patients usually experience 
chronic antipsychotic treatment. The chronic effects of aripiprazole on the GSK3β-
dependent signalling pathways, GABAA receptor and CREB1 are unknown. Therefore, 
the effects of 10-week administration of aripiprazole on these cellular signalling 
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aripiprazole and bifeprunox activated the Akt-GSK3β signalling in the PFC. In the NAc, 
chronic administration of all three drugs increased Akt-GSK3β signalling; while both 
aripiprazole and haloperidol up-regulated Dvl-3, β-catenin and GABAA receptors, as 
well as CREB1 activity. This study has confirmed the involvement of Dvl-GSK3β-β-
catenin, GABAA receptors and CREB1 activity in the long-term actions of aripiprazole.  
 
In brief, this thesis provided in vivo evidence that aripiprazole was able to activate the 
PKA, Akt-GSK3β and Dvl-GSK3β-β-catenin signalling pathways, and also up-regulate 
GABAA receptor expression, as well as CREB1 activity. Moreover, by comparing 
aripiprazole with haloperidol and bifeprunox, particularly their effects in the NAc, these 
studies further suggest that a relatively low intrinsic activity for D2Rs might be the key 
factor for aripiprazole to exert its unique clinical effects, and for other potential D2R 
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CHAPTER 1   GENERAL INTRODUCTION 1 
Schizophrenia is a devastating mental disorder, affecting approximately 1% of the 2 
general population world-wide (van Os and Kapur, 2009). Various antipsychotics are 3 
used to control the symptoms of schizophrenia. Their action at dopamine D2-like 4 
receptors (D2Rs) contributes to the therapeutic effects of all available antipsychotics 5 
(Kapur and Mamo, 2003). However, blockade of D2Rs by antipsychotics, especially the 6 
typical antipsychotics (e.g. haloperidol), induces unexpected side-effects, such as 7 
extrapyramidal side-effects (EPS) (Pierre, 2005). Aripiprazole is a unique antipsychotic 8 
drug that possesses favourable therapeutic effects, but with a very low rate of EPS (Di 9 
Sciascio and Riva, 2015). Aripiprazole’s partial agonism for the D2Rs is considered to 10 
be associated with its unique clinical profile of (Di Sciascio and Riva, 2015). However, 11 
all other D2R partial agonists that aimed to mimic aripiprazole have failed to achieve 12 
meaningful therapeutic effects in clinic trials. It was then proposed that the unique 13 
clinical profile of aripiprazole might be attributed to its functional selectivity for the 14 
D2R, which is supported by previous in vitro and in vivo evidence (Han et al., 2009; 15 
Lawler et al., 1999; Mailman, 2007; Shapiro et al., 2003). However, how aripiprazole 16 
regulates D2R-mediated cellular signalling pathways, as well as their downstream 17 
substrates, is not clear. Therefore, this thesis investigated the cellular mechanisms of 18 
aripiprazole in modulating the PKA- and GSK3β-dependent signalling pathways, by 19 
comparing it with a D2R antagonist – haloperidol – and a D2R partial agonist – 20 
bifeprunox. 21 
 22 
In summary, this thesis systematically investigated the in vivo effects of aripiprazole on 23 
several signalling pathways that are related to the pathophysiology of schizophrenia and 24 
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antipsychotics have stronger effects in the NAc than in other brain regions. Specifically, 1 
antipsychotics were able to affect the Dvl-GSK3β-β-catenin pathway, GABAA receptor 2 
expression and CREB in the NAc, but not in the other brain regions. Additionally, 3 
antipsychotics were able to alter the activity of GSK3β in both the NAc and PFC. 4 
Furthermore, aripiprazole displayed similar effects to haloperidol, but not bifeprunox, in 5 
the NAc, suggesting that aripiprazole is likely to exert antagonism for D2Rs due to its 6 
relatively low intrinsic activity for D2Rs; however, their effects in the PFC were 7 
different, probably indicating the therapeutic effects of aripiprazole on the negative and 8 
cognitive symptoms of schizophrenia. The results of this thesis provide in vivo evidence 9 
to develop further clues and strategies in the development of new antipsychotic drugs.  10 
  11 
The study in Chapter 3 showed the acute effects of aripiprazole on the D2R downstream 12 
cyclic adenosine monophosphate (cAMP)-protein kinase A (PKA) and protein kinase B 13 
(Akt)-glycogen synthase kinase 3-beta (GSK3β) signalling pathways. Rats were 14 
intraperitoneally injected once with aripiprazole (0.75 mg/kg), bifeprunox (0.8 mg/kg), 15 
haloperidol (0.1 mg/kg) or vehicle. The protein kinases PKA-C, Akt, phospho-Akt, 16 
GSK3β and phospho-GSK3β were examined in five brain regions – the prefrontal 17 
cortex (PFC), nucleus accumbens (NAc), caudate putamen (CPu), ventral tegmental 18 
area (VTA) and substantia nigra (SN). Aripiprazole presented similar effects on PKA-C 19 
expression to haloperidol, but not bifeprunox, in the CPu and VTA. Aripiprazole, but 20 
not bifeprunox and haloperidol, increased the phosphorylation levels of GSK3β in the 21 
PFC, NAc, CPu and SN. These results suggested acute administration of aripiprazole 22 
affected the cAMP-PKA and Akt-GSK3β signalling pathways differentially from 23 
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pharmacological profile of aripiprazole may be attributed to its relatively lower intrinsic 1 
activity for D2Rs. 2 
 3 
In Chapter 3, acute administration of aripiprazole displayed effects on PKA signalling, 4 
so this chapter continued to investigate the short-term effects of aripiprazole. 5 
Additionally, in the clinic, patients usually take drugs orally to treat the symptoms. 6 
Therefore, in Chapter 4, we orally administered animals with aripiprazole (0.250 mg/kg), 7 
bifeprunox (0.267 mg/kg,), haloperidol (0.033 mg/kg) or vehicle three times per day for 8 
1 week. In addition to the PKA signalling pathway, γ-aminobutyric acid (GABA)A 9 
receptor and cAMP-responsive element-binding protein 1 (CREB1) were examined due 10 
to their involvement in the pathophysiology of schizophrenia. The results showed that 11 
aripiprazole elevated PKA activity by increasing the levels of p-PKA and the ratio of p-12 
PKA/PKA only in the NAc. Correlated with this enhanced PKA activity, aripiprazole 13 
also increased expression of the GABAA (β-1) receptor and CREB1 in the NAc. 14 
Haloperidol elevated PKA activity by increasing p-PKA levels and the ratio of p-15 
PKA/PKA in both the NAc and CPu; while haloperidol increased the GABAA (β-1) 16 
receptor and CREB1 in the NAc, but not significantly. Lastly, bifeprunox had no effects 17 
on PKA signalling in these brain regions. This study suggested that aripiprazole 18 
increased the GABAA (β-1) receptor and CREB1 in the NAc, probably via activating 19 
PKA signalling, which cannot be achieved by haloperidol and bifeprunox.  20 
 21 
The results of Chapter 3 showed that acute administration of aripiprazole affected 22 
GSK3β, but not Akt. Since GSK3β is a multi-targeted kinase, antipsychotics may affect 23 
other GSK3β-dependent signalling pathways. The Dvl-GSK3β-β-catenin signalling 24 
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effects of 1-week administration of antipsychotics on the Dvl-GSK3β-β-catenin 1 
signalling pathway, along with the Akt-GSK3β signalling pathway were examined in 2 
Chapter 5. The results showed that aripiprazole increased GSK3β phosphorylation in 3 
the PFC, NAc and CPu, while haloperidol and bifeprunox had such effects only in the 4 
NAc and CPu, respectively. Additionally, both aripiprazole and haloperidol, but not 5 
bifeprunox, increased Dvl-3 and β-catenin expression in the NAc. This study suggested 6 
that activation of GSK3β phosphorylation in the PFC and NAc may be involved in the 7 
clinical effects of aripiprazole; it further indicated that the relatively low intrinsic 8 
activity for D2Rs might contribute to the effects of aripiprazole on the up-regulation of 9 
Dvl and β-catenin expression. 10 
 11 
It should be noted that in order to control the symptoms of schizophrenia, patients 12 
usually experience chronic antipsychotic treatment in clinics. Therefore, we investigated 13 
the chronic in vivo effects of aripiprazole in Chapter 6. In this study, the animals were 14 
orally administered aripiprazole (0.250 mg/kg), bifeprunox (0.267 mg/kg,), haloperidol 15 
(0.033 mg/kg) or vehicle three times per day for 10 weeks. The activity of PKA, Akt, 16 
GSK3β and CREB was examined by Western blots; the expression of Dvl-3, β-catenin 17 
and GABAA (containing β-1 subunit) receptor was also measured. After administration 18 
of aripiprazole and bifeprunox, activation of the Akt-GSK3β pathway was observed in 19 
the PFC. In the NAc, all three drugs induced Akt-GSK3β signalling; while both 20 
aripiprazole and haloperidol increased the expression of Dvl-3, β-catenin and GABAA 21 
receptors, as well as the phosphorylation levels of CREB. This study confirmed the 22 
involvement of Dvl-GSK3β-β-catenin, GABAA receptor and CREB activity in the NAc 23 
in the long-term actions of aripiprazole and haloperidol, suggesting that chronic 24 
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schizophrenia via these cellular signalling pathways. It is also suggested that the Akt-1 
GSK3β signalling pathway in the PFC is a possible route through which aripiprazole 2 
treats negative and cognitive symptoms of schizophrenia. Lastly, in comparison with the 3 
results of acute and short-term antipsychotic drug administration, antipsychotics might 4 
affect PKA and Akt-GSK3β signalling pathways in a time-dependent manner. 5 
 6 
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CHAPTER 2   LITERATURE REVIEW 1 
2.1 Characteristics of schizophrenia 2 
Schizophrenia is a group of persistent, chronic, severe and disabling mental disorders, 3 
affecting approximately 1% of the world’s general population (van Os and Kapur, 2009). 4 
The term “schizophrenia” was first used by Swiss psychiatrist Eugen Bleuler in 1911 5 
from the Greek roots schizein ("to split") and phrēn ("mind"), roughly meaning 6 
"splitting of the mind", because patients who developed schizophrenia seemed to 7 
vacillate between normal and abnormal states (Picchioni and Murray, 2007). Studies of 8 
schizophrenia have been carried out for decades since it was first characterised; 9 
however, the exact pathophysiology of schizophrenia still remains unclear. 10 
 11 
2.1.1 Symptoms of schizophrenia  12 
Schizophrenia symptoms are clinically characterised by positive symptoms, negative 13 
symptoms and cognitive deficits (Lisman et al., 2008). Positive symptoms represent an 14 
excess or distortion of normal functions and behaviours. Patients who develop positive 15 
symptoms usually manifest abnormal thoughts and behaviours, including hallucinations 16 
(auditory, visual, olfactory, etc.), delusions, disorganised thinking and speech and 17 
disorganised or catatonic behaviours (Bennett, 2008).  18 
 19 
Negative symptoms represent the loss or absence of normal traits or abilities. Patients 20 
with negative symptoms might experience social withdrawal, a reduction of emotional 21 
responsiveness, apathy, poverty of speech, inability to experience pleasure, memory 22 
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Cognitive deficits mainly include memory deficits, attenuated attention processes, and 1 
executive functioning impairment. Patients with cognitive deficits might experience 2 
delayed and impaired working memory, slowed cognitive speed, and impaired 3 
sequencing, organisation and flexibility (Gopal and Variend, 2005). 4 
 5 
2.2 Pathophysiological mechanisms of schizophrenia 6 
The exact pathophysiology of schizophrenia remains poorly understood. A variety of 7 
theories have been proposed to be associated with its pathophysiology. Several neuronal 8 
transmission systems are associated with the pathophysiology of schizophrenia, 9 
including the dopaminergic, GABA(γ-Aminobutyric acid)ergic and glutamatergic 10 
transmission systems (Elert, 2014; Insel, 2010). Among them, the present thesis focuses 11 
on the dopaminergic and GABAergic systems. 12 
 13 
2.2.1 The role of dopaminergic neurotransmission in the pathophysiology of 14 
schizophrenia  15 
2.2.1.1 Dopamine synthesis, release and reuptake 16 
Dopamine is produced in several areas of the brain, largely in the VTA and SN. 17 
Dopamine is biosynthesised by the hydroxylation of the amino acid tyrosine to 3,4-18 
dihydroxyphenylalanine (DOPA) via the enzyme tyrosine hydroxylase (TH) and then 19 
by the decarboxylation of DOPA by aromatic L-amino acid decarboxylase (AADC). 20 
After synthesis, dopamine is transported by vesicular monoamine transporter 2 21 
(VMAT2) into vesicles, which are then released into the synapse in response to a 22 
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remaining dopamine in the cleft is re-absorbed via the dopamine transporter (DAT) for  1 
recycling (Masson et al., 1999).  2 
 3 
2.2.1.2 Dopamine receptors 4 
The dopamine receptor is a class of G protein-coupled receptors (GPCRs). Five 5 
subtypes of dopamine receptors have been identified: D1, D2, D3, D4, and D5. The D1 6 
and D5 receptors are members of the D1-like family of dopamine receptors; the D2, D3 7 
and D4 receptors belong to the D2-like family (Missale et al., 1998). The structure of a 8 
dopamine receptor is illustrated in Fig. 2-1. Compared with D1-like receptors, D2Rs 9 
have a shorter COOH-terminal tail and a bigger third intracellular loop (I3). D1-like 10 
family receptors are coupled to the G protein Gα(s) (G stimulatory), which can stimulate 11 
adenylyl cyclase (AC), increasing the formation of the second messenger cyclic 12 
adenosine monophosphate (cAMP). D2-like family receptors interact with the G protein 13 
Gα(i) (G inhibitory), which can reduce AC activity, inhibiting the synthesis of cAMP.  14 
 15 
Although both D1- and D2-like receptors are involved in the pathophysiology of 16 
schizophrenia, the antipsychotics (aripiprazole, haloperidol and bifeprunox) examined 17 
in this thesis have strong affinity for D2-like, but not D1-like, receptors (Correll, 2010; 18 
Wadenberg, 2007). Therefore, we focused on D2Rs. Two isoforms of the D2R have been 19 
identified: the short-form D2 receptor (D2SR) and the long-form D2 receptor (D2LR) 20 
(Missale et al., 1998). The D2SR is pre-synaptically located, regulating 21 
neurotransmission via feedback mechanisms, being involved in the regulation of 22 
synthesis, storage, and release of dopamine (Girault and Greengard, 2004). The D2LR is 23 
a classical post-synaptic receptor, transmitting extracellular information into cells 24 








Fig. 2-1 The structure of a dopamine receptor.  3 
Potential phosphorylation sites are represented on 3rd intracellular loop (I3) and on 4 
COOH terminus. Potential glycosylation sites are represented on NH2 terminal. 5 
Abbreviations: E1–E3, extracellular loops; 1–7, transmembrane domains; 6 
I2–I3, intracellular loops; P, potential phosphorylation sites. 7 
 8 
 9 
2.2.1.3 Dopaminergic neurotransmission pathways in the brain 10 
There are three major dopaminergic neurotransmission pathways – the nigrostriatal 11 
pathway (Fig. 2-2A), mesolimbic pathway (Fig. 2-2B) and mesocortical pathway (Fig. 12 
2-2C); it has been proposed that these pathways are associated with the pathophysiology 13 
of schizophrenia and the action of antipsychotics. In the mesolimbic pathway (Fig. 14 
2-2B), dopaminergic neurons project from the VTA to the nucleus accumbens (NAc) in 15 
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from the VTA to the prefrontal cortex (PFC). In the nigrostriatal dopaminergic pathway, 1 
dopaminergic neurons project from the SN to the caudate putamen (CPu) in the striatum.  2 
 3 
 4 
Fig. 2-2 The three major dopaminergic neurotransmission pathways in the human brain.  5 
A. Nigrostriatal pathway. B. Mesolimbic pathway.  6 
C. Mesocortical pathway.  7 
Abbreviations: PFC = prefrontal cortex; CPu = caudate putamen; NAc = nucleus 8 
accumbens; SN = substantia nigra; VTA = ventral tegmental area. 9 
 10 
 11 
2.2.1.4 Dopamine hypothesis of schizophrenia 12 
The dopamine hypothesis of schizophrenia initially focused on excess 13 
neurotransmission at dopamine receptors (especially D2Rs) and blockade of these 14 
receptors to treat the psychosis, which was based on the observations that psychotic 15 
symptoms similar to those seen in schizophrenia were induced by administration of 16 
amphetamine and other compounds that increase extracellular concentrations of 17 
dopamine; and drugs that deplete dopamine levels reduced psychotic symptoms (Creese 18 
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Later, new evidence showed that impaired dopamine activity in the PFC results in 1 
increased levels of dopamine, dopamine metabolite and D2R density in the striatum 2 
(Howes and Kapur, 2009; Pycock et al., 1980). Regional specificity and cortical-3 
subcortical interactions of dopamine neurotransmission have been added into the 4 
hypothesis, which further proposed that schizophrenia is characterized by hypo-5 
dopaminergia in the PFC resulting in hyper-dopaminergia in the NAc (Howes et al., 6 
2015; Howes and Kapur, 2009). More specifically, it is hypothesised that hypo-7 
dopaminergia in the PFC results in the cognitive deficits of schizophrenia and striatal 8 
hyper-dopaminergia in the NAc results in the positive symptoms (Howes et al., 2015; 9 
Howes and Kapur, 2009). Nowadays, abnormal dopamine synthesis and dopamine 10 
release have been taken into account. Radiolabelled L-DOPA was used in positron 11 
emission tomography (PET) studies and increased dopamine synthesis from presynaptic 12 
terminals has been found in schizophrenic subjects compared with healthy controls in 13 
these studies (Demjaha et al., 2012; Hietala et al., 1999; Howes et al., 2009; Howes et 14 
al., 2013; Lindstrom et al., 1999; McGowan et al., 2004; Meyer-Lindenberg et al., 2002; 15 
Reith et al., 1994). Moreover, studies using radiotracers [11C]-raclopride and [123I]-16 
IBZM (they can compete with dopamine to bind with D2Rs) have revealed that 17 
dopamine release is increased in schizophrenic patients (Abi-Dargham et al., 1998; Abi-18 
Dargham et al., 2009; Breier et al., 1998; Egerton et al., 2010; Laruelle et al., 1999; 19 
Mizrahi et al., 2012; Pogarell et al., 2012). Therefore, it is suggested that presynaptic 20 
dopamine dysfunction, which leads to elevated levels of synaptic dopamine, is 21 
associated with the symptoms of schizophrenia; in addition, higher striatal dopamine 22 
synthesis capacity and dopamine release result in cortical dysfunctions (Fusar-Poli et al., 23 
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2.2.2 The role of GABAergic neurotransmission in the pathophysiology of 1 
schizophrenia 2 
2.2.2.1 GABA synthesis, release and reuptake 3 
GABA is the chief inhibitory neurotransmitter in the mammalian central nervous system. 4 
GABA is synthesised from glutamate using L-glutamic acid decarboxylase (GAD) and 5 
pyridoxal phosphate as a cofactor (Petroff, 2002) and then transported and stored in the 6 
vesicles through vesicular GABA transporter. Free GABA in the synaptic cleft is re-7 
uptaken by GABA transporter into the pre-synapse and stored in the vesicles; it is also 8 
transported into glial cells and converted into succinic semialdehyde and glutamate by 9 
GABA transaminase (Petroff, 2002) (Fig. 2-3). 10 
 11 
2.2.2.2 The GABAA receptor 12 
Three general classes of GABA receptor have been identified: the GABAA GABAB and 13 
GABAC receptor. The GABAA and GABAC receptor are ionotropic receptors, which are 14 
a ligand-gated ion channel complex; the GABAB metabotropic receptors are GPCRs 15 
that open or close ion channels via G proteins (Hendry et al., 1989). Among these three 16 
classes of GABA receptor, the GABAA receptor is an important therapeutic target in the 17 
brain because of its strong connection with schizophrenia (see section 2.2.2.3). The 18 
GABAA receptor is a pentameric transmembrane receptor that consists of five subunits: 19 
two α-, two β-, and one γ-subunits arranged around a central pore (Braat and Kooy, 20 
2015; Fritschy and Panzanelli, 2014). The major types of subunits that have been 21 
identified are the α1-6, β1-3, and γ1-3 subunits, among which the α1, α2 and α3 subunits, 22 
along with the β subunit variants and the γ2 subunit are highly expressed in postsynaptic 23 








Fig. 2-3 The synthesis, release, reuptake of glutamate. 3 
Abbreviations: GABA = γ-aminobutyric acid; GAT = GABA transporter; vGAT = 4 
vesicular GABA transporter 5 
 6 
 7 
Two GABA molecules bind with the receptor at the interface between an α and a β 8 
subunit (Fritschy and Panzanelli, 2014). Once bound to GABA, the protein receptor 9 
changes conformation within the membrane, opening the pore in order to allow Cl− to 10 
pass down an electrochemical gradient, resulting in hyperpolarisation of the neuron 11 
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								  1 
Fig. 2-4 Schematic diagram of the GABAA receptor. 2 
Left: The receptor consists of five subunits, which are symmetrically arranged, forming 3 
a central Cl− ion channel pore.  4 
Right: Five subunits form the receptor, the Cl− ion channel pore and the two GABA 5 
active binding sites at the α and β interfaces. 6 
 7 
 8 
2.2.2.3 Abnormal GABA receptors in schizophrenia 9 
Of the three classes of GABA receptors, GABAA receptors are the most complex. The 10 
abundant allosteric binding sites on these receptors could be targeted by various drugs 11 
and treatments, making GABAA receptors an important therapeutic target (Wassef et al., 12 
2003). The relationship between abnormalities in GABAA receptors and schizophrenia 13 
is obvious. Post-mortem studies reported increased binding density of [3H]-muscimol or 14 
[3H]-GABA to the total population of GABAA receptors in various brain regions, 15 
including the dorsolateral prefrontal cortex, caudate nucleus, posterior and anterior 16 
cingulate cortex, superior temporal gyrus and hippocampal formation in patients with 17 
schizophrenia (Benes et al., 1992; Dean et al., 1999; Deng and Huang, 2006; Ishikawa 18 
et al., 2004; Nakazawa et al., 2012; Newell et al., 2007; Woo et al., 2004). The 19 
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response to defective inhibitory modulation, probably caused by a decreased number of 1 
inhibitory interneurons, or impaired release and/or transport of GABA (Nakazawa et al., 2 
2012). These changes in GABAA receptors in the schizophrenic brain may represent a 3 
primary pathogenesis, which might be associated with the symptoms of schizophrenia 4 
(Nakazawa et al., 2012). Since GABA plays an inhibitory role in counter-balancing 5 
glutamate-mediated neuronal excitation, abnormalities in the communication between 6 
them might result in a loss of inhibitory tone and consequent disinhibition of excitatory 7 
pyramidal cells, leading to neuronal dysfunctions in other brain regions, which finally 8 
may cause the impaired cognitive functions observed in schizophrenia (Looijestijn et al., 9 
2015; Nakazawa et al., 2012).  10 
 11 
2.3 Antipsychotics 12 
2.3.1 Typical antipsychotics 13 
Typical antipsychotics (also known as first-generation antipsychotics), discovered in the 14 
1950s, were the first effective antipsychotic drugs to treat some of the symptoms of 15 
schizophrenia. Typical antipsychotics are effective to ameliorate the positive symptoms 16 
in schizophrenia, such as hallucinations, delusions and thought disorder. So far, a 17 
number of antipsychotics have been developed and approved for use clinically to treat 18 
psychosis, especially schizophrenia, including fluphenazine (Prolixin), haloperidol 19 
(Haldol), thioridazine (Mellaril), trifluoperazine (Stelazine), pipotiazine (Piportil) and 20 
perphenazine (Trilafon). Typical antipsychotics have high affinity specifically for D2Rs 21 
(e.g. haloperidol Ki value: 2.6 nM for D2 receptors, 2 nM for D3 receptors and 3 nM for 22 




Bo Pan 16 
 
2012; Seeman, 2010). Typical antipsychotics achieve their clinical therapeutic effects 1 
mainly by potently blocking D2Rs (Correll, 2010).  2 
 3 
Although typical antipsychotics are effective in treating the positive symptoms in 4 
schizophrenia, they have few effects in treating negative symptoms or cognitive deficits 5 
(Agid et al., 2008). Due to blockade of the D2R in the nigrostriatal dopaminergic 6 
pathway, typical antipsychotics can cause EPS (e.g. tardive dyskinesia and akathisia) 7 
and hyperprolactinemia, as well as body weight gain to some extent (Bishara and Taylor, 8 
2008; Pierre, 2005).  9 
 10 
Table 2-1 Receptor affinities of main typical and atypical antipsychotic drugs, 11 
including aripiprazole.  12 
Receptor HAL OLAN CLOZ ARI BIF 
D1 210 31 85 265 ─ 
D2 2.6 20 210 0.66 8.5 
D3 2 49 473 0.8 9.1 
D4 3 27 35 44 8 
5-HT1A 1,800 610 160 5.5 8.2 
5-HT2A 61 1.5 2.59 8.7 ─ 
5-HT2C 4,700 4.1 4.8 26 ─ 
α1 17 44 6.8 74 ─ 
α2 600 280 158 ─ ─ 
H1 260 0.08 3.1 30 ─ 
M1 >10,000 2.5 1.4 6,780 ─ 
Note: All values are reported as Ki (nM). 13 
Abbreviations: HAL = haloperidol; OLAN = olanzapine; CLOZ = clozapine; 14 
ARI = aripiprazole; BIF = bifeprunox; D1 = dopamine1; D2 = dopamine2; D3 15 
= dopamine3; D4 = dopamine4; 5-HT1A = serotonin1A; 5-HT2A = serotonin2A; 16 
5-HT2C = serotonin2C; H1 = histamine1; M1 = muscarinic1. 17 
(Modified from Correll, 2010; Wadenberg, 2007) 18 
 19 
 20 
2.3.2 Atypical antipsychotics 21 
In the 1960s, the first atypical antipsychotic drug (also known as the second-generation 22 
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1970s. After clozapine, other atypical antipsychotic drugs, including risperidone 1 
(Risperdal), olanzapine (Zyprexa), quetiapine (Seroquel) and ziprasidone (Geodon), 2 
were developed and used clinically in treating symptoms in schizophrenia. Atypical 3 
antipsychotic drugs are effective to some degree in alleviating positive and negative 4 
symptoms, as well as cognitive deficits of schizophrenia, with reduced EPS (Kane and 5 
Correll, 2010; Meltzer, 2013). 6 
 7 
The atypical antipsychotics have a lower affinity for D2Rs than the typical 8 
antipsychotics (Meltzer, 2013), but they can bind with various other receptors (Table 9 
2-1). Atypical antipsychotics are predominantly antagonists for serotonin [5-hydroxy-10 
tryptamine (5-HT)]2A receptors (e.g. olanzapine Ki value: 1.5 nM; clozapine Ki value: 11 
2.59 nM; aripiprazole Ki value: 8.7 nM) (Correll, 2010). In addition, atypical 12 
antipsychotics have affinity for 5-HT1A receptors (e.g. aripiprazole Ki value: 5.5 nM), 5-13 
HT2C receptors (e.g. olanzapine Ki value: 4.1 nM; clozapine Ki value: 4.8 nM), α 14 
adrenergic receptors (e.g. clozapine Ki value: 6.8 nM), histamine H1 receptors (e.g. 15 
olanzapine Ki value: 0.08 nM; clozapine Ki value: 3.1 nM), as well as muscarinic M 16 
receptors (e.g. olanzapine Ki value: 2.5 nM; clozapine Ki value: 1.4 nM) (Correll, 2010).  17 
 18 
Because of their reduced blockade of the D2R, atypical antipsychotics cause EPS at a 19 
much lower rate; however, they (e.g. olanzapine, clozapine) are associated with severe 20 
weight gain/obesity side-effects, and other metabolic diseases such as type II diabetes, 21 
dyslipidaemia and insulin resistance (Milano et al., 2013). Accumulated evidence has 22 
shown that these side-effects induced by olanzapine and clozapine may be partly due to 23 
the blockade of H1 receptors, 5-HT2C receptors and M3 receptors (Deng et al., 2010; 24 
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2.3.3 Aripiprazole  1 
Aripiprazole [7-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]-butyloxy]-3,4-dihydro-2(1H)-2 
quinolinone], a dihydrocarbostyril derivative (Fig. 2-5), is an atypical antipsychotic 3 
drug. Aripiprazole showed efficacy and well tolerability in clinical trials over different 4 
periods for the treatment of schizophrenia and schizoaffective disorder (Stip and 5 
Tourjman, 2010). It was also shown to be effective and well tolerated in the manic and 6 
maintenance phases of bipolar disorder (Aitchison et al., 2009; Dratcu et al., 2012).  7 
 8 
 9 
Fig. 2-5 The chemical structure of aripiprazole 10 
 11 
 12 
Aripiprazole has a novel receptor action profile, which is different from those of all 13 
other available first- and second-generation antipsychotic drugs. For this reason, it is 14 
also called “the third-generation antipsychotic drug” by some researchers (Mailman and 15 
Murthy, 2010). Aripiprazole was first developed as a D2R partial agonist (Burris, 2002; 16 
Wood and Reavill, 2007). It exhibits high affinity for the dopaminergic receptors (Ki 17 
value: 0.45 nM for D2 receptors and 0.8 nM for D3 receptors) (Table 2-1) (Correll, 2010) 18 
and possesses high occupancy for the D2R, ranging between approximately 71% at 2 19 
mg/day to 96% at 40 mg/day (Kegeles et al., 2008; Yokoi et al., 2002). Furthermore, 20 
aripiprazole displays partial agonism for the serotonin 5-HT1A receptor and antagonism 21 




Bo Pan 19 
 
also has moderate affinity for histamine, α-adrenergic, and D4 receptors (Di Sciascio 1 
and Riva, 2015). 2 
 3 
Despite of its high affinity for and occupancy of the D2Rs (Correll, 2010; Kegeles et al., 4 
2008; Yokoi et al., 2002), aripiprazole, compared with typical antipsychotics (e.g. 5 
haloperidol), induces a much lower rate of hyperprolactinemia and EPS which are 6 
associated with excessive blockade of dopamine receptors (Poyurovsky et al., 2008). It 7 
is due to its partial agonism for the D2R that it produces a much lower level of 8 
functional antagonism of D2R-mediated neurotransmission than that induced by full 9 
D2R antagonists (Kegeles et al., 2008; Mamo et al., 2007; Shapiro et al., 2003; Strange, 10 
2008). 11 
 12 
2.3.4 Pharmacological mechanisms of aripiprazole 13 
2.3.4.1 Comparison between aripiprazole and other D2 receptor partial agonists 14 
As mentioned above, aripiprazole was the first D2R partial agonist, approved for use in 15 
the clinic as an antipsychotic drug. However, to date, with the exception of aripiprazole, 16 
other D2R partial agonists were not able to achieve meaningful clinical efficacy or were 17 
abandoned due to tolerability and/or safety issues. The relative intrinsic activity of 18 
aripiprazole and other D2R partial agonists tested previously compared with that of 19 
dopamine (shown as 100%) is listed in Table 2-2. Clinical trials indicated that these 20 
D2R partial agonists possessed various therapeutic effects and/or side-effects. For 21 
example, OPC-4392 [7-[3-(4-[2,3-Dimethylphenyl]piperazinyl)propoxy]-2(1H)-22 
quinolinone] exhibited therapeutic effects on negative symptoms, but not positive 23 
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8α-ergolinyl)urea] failed for a reason similar to OPC-4392 (Benkert et al., 1995) and it 1 
is primarily used as a serotonin antagonist (Janssen et al., 2015);  SDZ 208-912 [N-[8α]-2 
2-chloro-6-methylergoline-8-yl]-2,2-dimethylpropanamide], with the lowest intrinsic 3 
activity for D2R in the list (Table 2-2), could improve the psychiatric rating scale for the 4 
assessment of both positive and negative symptoms in clinical trials, but also induced 5 
side-effects similar to those observed after haloperidol treatment (Benkert et al., 1995); 6 
(-)-3PPP (preclamol) [(-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine] displayed 7 
apparent antipsychotic effects at the beginning of treatment in the clinical test, but its 8 
antipsychotic action was not sustained for longer than 1 week (Lahti et al., 1998).  9 
 10 
Bifeprunox [7-[4-(biphenyl-3-ylmethyl)piperazin-1-yl]-1,3-benzoxazol-2(3H)-one] 11 
shares a similar pharmacological profile with aripiprazole. Both of them are partial 12 
agonists for D2Rs and serotonin 5-HT1A receptors (Newman-Tancredi et al., 2007). 13 
They also present similar affinity with these receptors (Table 2-1). In vivo studies have 14 
shown that both bifeprunox and aripiprazole decreased the firing activity and bursting 15 
activity of dopamine neurons in the rat VTA (Dahan et al., 2009; Etievant et al., 2009). 16 
Bifeprunox possesses potent effects in animal models of psychosis, without inducing 17 
cataleptogenic activity (Bardin et al., 2006; Hesselink et al., 2005). In a 6-week, double-18 
blind, placebo-controlled study, bifeprunox was efficacious in reducing symptoms in 19 
patients with an acute exacerbation of schizophrenia, with a safe EPS liability profile 20 
(Casey et al., 2008; Wadenberg, 2007). However, it was still disapproved and cancelled 21 
due to lack of meaningful effects on non-acute patients with schizophrenia; it also 22 
induced severe side effects (e.g. nausea) and safety issues (Lundbeck, 2009). Although 23 
it was abandoned, bifeprunox has been chosen as a reference drug to compare with 24 
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Table 2-2 Relative intrinsic activity of dopamine, aripiprazole and other D2R partial 1 
agonists at D2L and D2S receptors in the CHO cell lines 2 
Drugs D2L receptors D2S receptors 
Dopamine 100% 100% 
Bifeprunox 95.1% 99.1% 
Terguride 94% 101% 
OPC-4392 93.3% 98.6% 
(-)-3PPP 93% 100% 
Aripiprazole 86% 94.5% 
SDZ 208-912 57.3% 85% 
(Modified from Tadori et al., 2007; Tadori et al., 2005) 3 
 4 
 5 
2.3.4.2 Evidence of functional selectivity of aripiprazole 6 
As the study of aripiprazole progressed, some evidence indicated that partial agonism 7 
for D2Rs with moderate intrinsic activity might not be the only reason for the unique 8 
effects of aripiprazole. Some researchers proposed that the unique pharmaceutical 9 
property of aripiprazole is also attributed to its functional selectivity for D2Rs (Lawler et 10 
al., 1999; Mailman, 2007; Shapiro et al., 2003).  11 
 12 
The concept of functional selectivity is different from traditional pharmacology. 13 
Traditional pharmacology posits that a ligand can be classified either as an agonist (full 14 
or partial), antagonist or an inverse agonist through a single receptor isoform, and that 15 
this characteristic will be consistent with all effector (second messenger) systems 16 
coupled to that receptor. In contrast, functional selectivity posits that a ligand can 17 
produce functional multiple effects for certain signal transduction pathways when 18 
interacting with a single receptor isoform (Mailman and Murthy, 2010). This can be 19 
presented when a single receptor has several possible signal transduction pathways. A 20 
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 1 
Fig. 2-6 A schema of comparison between a typical ligand and a functionally selective 2 
ligand. 3 
A functionally selective ligand acting at a single receptor might cause an altered balance 4 
of therapeutic and side effects, whereas a typical ligand induces therapeutic and side 5 
effects equally. 6 
(Modified from Mailman and Murthy, 2010) 7 
 8 
 9 
conformation changes of G-proteins (compared to the endogenous ligand), which in 10 
turn can induce unique activation of downstream pathways. The degree to which each 11 
pathway is activated depends on both the intracellular (the type of cell) and extracellular 12 
(the location in the cell) environment (Mailman and Murthy, 2010). For example, when 13 
the “typical” ligand (Fig. 2-6, left panel) acts at a single receptor, two intracellular 14 
signalling pathways are activated, one associated with the therapeutic effect, the other 15 
with the side effect. In contrast, the functionally selective ligand (Fig. 2-6, right panel) 16 
preferentially activates the intracellular pathway that is linked to the therapeutic effect, 17 
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side effect induced by this single receptor. Therefore, compared with traditional ligands, 1 
a ligand with functional selectivity cannot be classified simply as an agonist or 2 
antagonist for a single receptor, because it can be both, depending on its preferred signal 3 
transduction pathways. 4 
 5 
There are several lines of the evidence that support the functionally selective effects of 6 
aripiprazole. In vitro studies have indicated that aripiprazole elicited agonism for 7 
presynaptic D2 autoreceptors, but antagonised postsynaptic D2Rs (Kikuchi et al., 1995; 8 
Shapiro et al., 2003). Another in vitro study suggested that aripiprazole acted as a potent 9 
partial agonist to the D2R-mediated signalling responses (such as potentiation of 10 
arachidonic acid release), and as a weak partial agonist using MAPK phosphorylation, 11 
but lacked agonist activity on receptor internalisation (Urban et al., 2007). Koener et al. 12 
(2012) suggested that aripiprazole displayed functionally selective effects on D2Rs, 13 
depending not only on receptor density but also on the surrounding cellular environment. 14 
Furthermore, an in vivo study demonstrated that aripiprazole had selective effects on the 15 
mesolimbic vs. the nigrostriatal dopaminergic pathways (Han et al., 2009). This study 16 
found that aripiprazole significantly increased D2R mRNA expression and decreased 17 
TH mRNA expression in the VTA after both 1- and 12-week treatment, but had no 18 
effect on the SN; in contrast, haloperidol displayed non-selective influences on both the 19 
mesolimbic and nigrostriatal dopaminergic pathways (Han et al., 2009). It is worth 20 
noting that aripiprazole had no effect on D2R mRNA expression and D2R binding in the 21 
NAc and CPu, suggesting that the regulation of dopamine synthesis and release through 22 
the D2 autoreceptors in the mesolimbic pathway may contribute to the therapeutic 23 
effects of aripiprazole (Han et al., 2009). Additionally, the absence of influence on D2Rs 24 
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Findings from these studies cannot be explained simply by its partial agonism for D2Rs. 1 
Taken together, it seems likely that aripiprazole does not affect the signalling pathways 2 
mediated by D2Rs globally; instead, aripiprazole could interact with signalling pathways 3 
in a brain-region-selective manner. However, further studies, in particular in vivo 4 
studies, are still required to validate the functional selective property of aripiprazole. 5 
 6 
2.4 Effect of antipsychotics on various receptors and cellular signalling pathways 7 
2.4.1 Effect of antipsychotics on D2R downstream signalling pathways 8 
As described in section 2.3, nearly all antipsychotics can act at D2Rs, and the 9 
dopaminergic neurotransmission pathways are major pathways through which 10 
antipsychotics elicit their therapeutic effects and side-effects (e.g. EPS); additionally, 11 
aripiprazole might selectively affect the D2R-mediated downstream signalling pathways. 12 
The dopamine D2 receptor mediates two major downstream signalling pathways: the G-13 
protein-dependent cAMP-PKA signalling pathway and Akt-GSK3β signalling pathway.  14 
 15 
2.4.1.1 Effect of antipsychotics on cAMP-PKA signalling pathway 16 
The cAMP-PKA signalling pathway 17 
The D2R is a kind of G-protein-coupled receptor, transmitting signals via coupled G-18 
proteins, which consists of Gα, Gβ and Gγ subunits. Without a ligand agonist, the Gα 19 
subunit is bound to guanosine diphosphate (GDP) and the complex of Gβ and Gγ 20 
subunits (Gβγ complex). Upon stimulus of the ligand, GDP will be released and 21 
guanosine triphosphate (GTP) will be bound with the Gα subunit instead of GDP. The 22 
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stimulate AC, restraining the production of cAMP derived from adenosine triphosphate 1 
(ATP) and further inhibiting the activity of protein kinase A (PKA) (Fig. 2-7).  2 
 3 
 4 
Fig. 2-7 The cAMP-PKA signalling pathway of the dopamine D2 receptor. 5 
Abbreviations: AC = adenylate cyclase; ATP = adenosine triphosphate; cAMP = 6 
cyclic adenosine monophosphate; GDP = guanosine diphosphate; GTP = guanosine 7 
triphosphate; PKA = protein kinase A.  8 
 9 
 10 
One previous study reported that the short-form D2 autoreceptor interacts preferentially 11 
with the cAMP pathway to control synthesis, release and uptake of dopamine (Meyer-12 
Lindenberg et al., 2002). Additionally, TH was found to be phosphorylated by the 13 





















Fig. 2-8 Modulation of D2 autoreceptor on the synthesis, release and re-uptake of 3 
dopamine. 4 
Abbreviations: AADC = Aromatic L-amino acid decarboxylase; DA = dopamine; 5 
DAT = dopamine transporter; DOPA = 3,4-dihydroxyphenylalanine; PKA = 6 
protein kinase A; MAPK = mitogen-activated protein kinase; TH = Tyrosine 7 
hydroxylase; VMAT2 = vesicular monoamine transporter 2.  8 
 9 
 10 
Effect of antipsychotics on the cAMP-PKA signalling pathway 11 
There is significant evidence that antipsychotic drug administration has various effects 12 
on the cAMP-PKA signalling pathway. Experiments using bioluminescence resonance 13 
energy transfer (BRET) have suggested that all classes of antipsychotics (including 14 
haloperidol, aripiprazole, clozapine, chlorpromazine, quetiapine, olanzapine, risperidone 15 
and ziprasidone) can differentially affect the cAMP-PKA pathway through the long 16 
dopamine (D2L) receptor mediated Gα(i/o) protein (Klewe et al., 2008; Masri et al., 2008). 17 
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inhibited cAMP binding to the subunit of PKA, reducing its protein levels of RIIα, RIIβ, 1 
and Catβ-subunit isoforms, as well as their respective mRNA expression; however, 2 
chronic treatment (21 days) with haloperidol significantly increased the activity of 3 
cAMP-PKA pathway in the striatum, as well as mRNA and protein levels of the RIIα 4 
and RIIβ subunit isoforms in the striatum (Dwivedi et al., 2002). Lastly, it has been 5 
reported that aripiprazole inhibited AC activity and cAMP accumulation in vitro (Burris, 6 
2002; Lawler et al., 1999; Shapiro et al., 2003). 7 
 8 
It has also been reported that antipsychotic treatment is able to affect dopamine 9 
autoreceptors, regulating dopamine synthesis and re-absorption through cAMP-PKA 10 
signalling. For example, Onali and colleagues (1992) have reported that activation of D2 11 
autoreceptors induced a decrease in the cAMP-dependent activation of TH both in vivo 12 
and in vitro. Aripiprazole may elicit its therapeutic effects in animals through causing 13 
the D2 autoreceptors to regulate dopamine synthesis, release and reuptake (Han et al., 14 
2009). 15 
 16 
2.4.1.2 Effect of antipsychotics on Akt-GSK3β signalling pathway 17 
The Akt-GSK3β signalling pathway 18 
In addition to the G-protein-dependent cAMP-PKA signalling pathway, the dopamine 19 
D2 receptor also transmits signals via the G-protein-independent β-arrectin2-Akt-20 
Glycogen synthase kinase 3 (GSK3) signalling pathway. GSK3 is a serine/threonine 21 
protein kinase, having two isoforms, GSK3α and GSK3β, ubiquitously expressed in all 22 
mammalian tissue and subcellular organelles (Hur and Zhou, 2010). GSK3 is different 23 
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activity when phosphorylated by Akt at an N-terminal serine residue (Hur and Zhou, 1 
2010).  2 
 3 
Fig. 2-9 The dopamine D2 receptor-mediated β-arrestin2-Akt-GSK3β signalling 4 
pathway  5 
Abbreviations: Akt = protein kinase B; GSK3β = glycogen synthase kinase 3-beta.  6 
 7 
 8 
Accumulated evidence indicates that in addition to the canonical signalling pathways 9 
via G proteins, the recruitment of β-arrestin2 to the D2R can also activate cellular 10 
signalling in a G protein-independent manner by inducing the formation of a signalling 11 
complex that comprises at least β-arrestin2, Akt and protein phosphatase 2A (PP2A) 12 
(Beaulieu et al., 2005; Lefkowitz and Shenoy, 2005) (Fig. 2-9). A previous study 13 
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apomorphine, a non-selective dopamine receptor agonist (Beaulieu et al., 2005) and 1 
impaired locomotor responses to the dopamine-dependent actions of amphetamine and 2 
morphine (Beaulieu et al., 2005; Bohn et al., 2003). Taken together with the results of 3 
the study on the D2R antagonist haloperidol in non-transgenic animals (Emamian et al., 4 
2004), a β-arrestin2-mediated cAMP-independent D2R-regulated signalling pathway 5 
that involves Akt and GSK3β has been considered to be related to the above abnormal 6 
responses to the D2R ligands in the β-arrestin2-knockout animals (Beaulieu et al., 2007; 7 
Beaulieu et al., 2006; Beaulieu et al., 2005; Beaulieu et al., 2004). It was also reported 8 
that activation of D2R signalling via the β-arrestin2-PP2A-Akt complex deactivates Akt, 9 
followed by inhibition of GSK3β phosphorylation (stimulation of GSK3-mediated 10 
signalling) (Beaulieu et al., 2007, 2009; Beaulieu et al., 2004).  11 
 12 
Effect of antipsychotics on the Akt-GSK3β signalling pathway 13 
Both in vitro and in vivo studies have demonstrated the effects of antipsychotics on the 14 
Akt-GSK3β pathway, although the results are, to some degree, inconsistent. Among 15 
these studies, antipsychotics with antagonism for the D2R (e.g. haloperidol) were shown 16 
to elevate Akt phosphorylation and increase concomitant GSK3β phosphorylation 17 
(Beaulieu et al., 2004; Emamian et al., 2004). In addition, several studies have reported 18 
that both acute and chronic treatment of first-generation (e.g. haloperidol) and second-19 
generation (e.g. clozapine, olanzapine, risperidone, quetiapine, and ziprasidone) 20 
antipsychotics increased the levels of both GSK3β and phosphor-Ser-GSK3β in several 21 
brain regions of rodents, including the striatum, cortex and hippocampus (Alimohamad 22 
et al., 2005a; Beaulieu et al., 2009; Li et al., 2007). Furthermore, in vitro studies using 23 
BRET have demonstrated that antipsychotics (except aripiprazole), independent of class, 24 
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pathway, but have various effects on the D2L receptor-mediated cAMP-PKA signalling 1 
pathway (Klewe et al., 2008; Masri et al., 2008). Lastly, a BRET study has indicated 2 
that aripiprazole antagonised β-arrestin2 recruitment to the D2L receptor (Masri et al., 3 
2008); however, another BRET experiment has found that aripiprazole (as a partial 4 
agonist) was incapable of stimulating recruitment of β-arrestin2 to the D2L receptor in 5 
vitro (Klewe et al., 2008). These inconsistent results require further validation. 6 
 7 
In summary, several in vitro studies have examined the effects of aripiprazole on the 8 
D2-coupled intracellular pathways; however, the in vivo effects of aripiprazole on the 9 
D2-coupled intracellular pathways are not clear and need to be investigated; in particular, 10 
no study has investigated whether aripiprazole affects the cellular dopaminergic 11 
pathways differently in different brain regions. 12 
 13 
2.4.2 Effects of antipsychotics on Dvl-GSK3β-β-catenin signalling pathway 14 
Wnts (Wingless/Int-1) are secreted glycolipoproteins that can activate canonical (β-15 
catenin dependent) and non-canonical Wnt signalling pathways (Panaccione et al., 16 
2013). The canonical Wnt-Dvl-GSK3β-β-catenin signalling pathway plays a critical role 17 
in diverse neuronal processes including cell proliferation, migration, differentiation and 18 
cell fate during the development of the central nervous system (Davis and Ghosh, 2007; 19 
Lu and Van Vactor, 2007; McMahon and Bradley, 1990; Ohigashi et al., 2005), and has 20 
been considered to be related to the pathophysiology of schizophrenia and can be 21 
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The Dvl-GSK3β-β-catenin signalling pathway is illustrated in Fig. 2-10. Without the 1 
binding of Wnt to the seven-pass transmembrane Frizzled family receptor, a 2 
“destruction complex” containing Axin, adenomatosis polyposis coli (APC), casein 3 
kinase 1 (CK1) and GSK3 functions (Hart et al., 1998; Ikeda et al., 1998; Minde et al., 4 
2011; Zeng et al., 1997). Within this protein complex, CK1 phosphorylates β-catenin at 5 
Ser45, which generates a priming site for subsequent GSK3β phosphorylation at Thr41 6 
(Amit et al., 2002; Hagen et al., 2002; Hagen and Vidal-Puig, 2002; Liu et al., 2002; 7 
Sakanaka, 2002; Yanagawa et al., 2002) and subsequently at Ser37 and Ser33. This 8 
results in the recognition of β-catenin by β-TrCP (an E3 ubiquitin ligase subunit), and 9 
subsequent ubiquitination-mediated digestion by proteasomal in the proteasome (Aberle 10 
et al., 1997; Amit et al., 2002; He et al., 2004; Liu et al., 2002). In addition, both Axin 11 
and APC are phosphorylated by GSK3β. Phosphorylated Axin and APC increase their 12 
stability and affinity to β-catenin (Ikeda et al., 1998; Jho et al., 1999; Rubinfeld et al., 13 
1996; Yamamoto et al., 1999), which promotes β-catenin phosphorylation and 14 
degradation complex stability. Once the Wnt binds to Frizzled receptors, Dvl is 15 
phosphorylated, followed by the phosphorylation of GSK3β and inhibition of its 16 
functions. The inhibition of GSK3β leads to interruption of the phosphorylation and 17 
degradation of β-catenin. Axin and APC also become de-phosphorylated due to the 18 
phosphorylation of GSK3β and their stability and affinity to β-catenin decreases. All 19 
these processes induced by Wnt signalling result in the accumulation of β-catenin in the 20 
cytoplasm. Accumulated β-catenin is then translocated into the nucleus to act as a 21 
transcriptional coactivator of transcription factors that belong to the T-cell factor and 22 
lymphoidenhancing factor (TCF/LEF) family, which activates the transcription of 23 
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 1 
Fig. 2-10 The Dvl-GSK3β-β-catenin signalling pathway.  2 
Abbreviations: APC = adenomatous polyposis coli; CK1 = casein kinase 1; 3 
Dvl = dishevelled; GSK3β = glycogen synthase kinase 3-beta. 4 
 5 
 6 
The effects of antipsychotic administration on the Dvl-GSK3β-β-catenin signalling 7 
pathway varied in previous studies. Sutton et al. (2007) have reported that treatment 8 
with haloperidol and clozapine induced over-expression of Dvl-3 in pheochromocytoma 9 
(PC12) and neuroblastoma (SH-SY5Y) cells. Sutton et al. (2007) have also found that 10 
daily injection with haloperidol or clozapine (but not aripiprazole) for 2 weeks resulted 11 
in increases in the levels of Dvl-3, total and phosphorylated GSK3β and β-catenin in the 12 
rat PFC. Significant increases in the levels of β-catenin and GSK3β total protein were 13 
induced by sub-chronic and chronic administration of haloperidol in the PFC, by 14 
risperidone and clozapine in the PFC and NAc, and by all three antipsychotics in the 15 
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2005b). Similarly, another in vivo study has found that 2-week administration of 1 
haloperidol and clozapine increased the protein levels of Dvl-3, total and 2 
phosphorylated GSK3β and β-catenin in the PFC; haloperidol (but not clozapine) 3 
administration also had similar effects in the striatum (Sutton and Rushlow, 2011). 4 
Moreover, Park et al. (2011a) and Seo et al. (2015) have indicated that systematic 5 
administration of aripiprazole and olanzapine for 3 weeks was able to restore the 6 
reduced phosphorylation levels of GSK3β and decreased β-catenin protein levels in the 7 
PFC and hippocampus caused by immobilisation stress. It is worth noting that 8 
antipsychotics do not have affinity with Dvl upstream Frizzled receptors. Therefore, it is 9 
important to reveal the pathways through which antipsychotics affect Dvl-GSK3β-β-10 
catenin signalling.  11 
 12 
2.4.3 Effect of antipsychotics on GABAA receptors 13 
As described in Section 2.2.2, abnormal GABA transmission is implicated in the 14 
pathophysiology of schizophrenia. Previous studies have reported increased GABAA 15 
receptor binding density in various brain regions in post-mortem tissue of schizophrenic 16 
subjects (Benes et al., 1996a; Benes et al., 1992; Benes et al., 1996b; Benes et al., 1997; 17 
Dean et al., 1999; Ishikawa et al., 2004; Newell et al., 2007; Woo et al., 2004). 18 
Antipsychotic drug administration showed influences on GABAA receptors in a brain 19 
region-dependent manner. Zink and colleagues (2004) have indicated that 20 
administration of haloperidol for 6 months increased binding density of [3H]-muscimol 21 
to GABAA receptors in the CPu, the core of the NAc, while reducing it in the PFC; in 22 
addition, both haloperidol and clozapine administration reduced the binding density of 23 
GABAA receptors, in the anterior cingulate and infralimbic cortex, respectively. 24 
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total population of GABAA receptors and [3H]-flunitrazepam to the benzodiazepine-1 
sensitive GABAA receptors was increased by administration of haloperidol and 2 
olanzapine in the PFC; however, longer treatment with these antipsychotics did not have 3 
significant effects. It has also been revealed that administration of haloperidol decreased 4 
GABA binding sites ([3H]-muscimol) in the thalamus, but increased binding sites in the 5 
hypothalamus; additionally, haloperidol administration induced a widespread decrease 6 
in the number of benzodiazepine binding sites ([3H]-flumazenil) (McLeod et al., 2008). 7 
Furthermore, a PET study employing [18F]-FFMZ has demonstrated that GABAA 8 
receptor binding potential was lower in the aripiprazole group than the risperidone 9 
group, but not controls, in the right medial PFC and right dorsolateral PFC; GABAA 10 
receptor binding potential was lower in the aripiprazole group than the risperidone and 11 
control groups in the left frontopolar cortex and right premotor cortex (Lee et al., 2013).   12 
 13 
However, since antipsychotics have very low affinity for GABA receptors and cannot 14 
directly affect GABA receptors, it is necessary to identify the cellular signalling 15 
pathways through which antipsychotics indirectly modulate GABAA receptors. This 16 
thesis will investigate some of these signalling pathways. For example, it is interesting 17 
that it has been reported that GABAA receptors can be regulated by PKA (Connelly et 18 
al., 2013; Poisbeau et al., 1999). Therefore, it is necessary to investigate whether 19 
aripiprazole regulates GABAA receptors, and whether PKA is involved in this 20 
regulation. 21 
 22 
2.4.4 Effect of antipsychotics on CREB 23 
CREB is a regulator targeted by several signalling pathways, such as the PKA 24 
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regulated kinase (ERK)1/2 signalling pathways, PT3K (phosphoinositide 3-kinase)/Akt 1 
pathway, and stress induced signalling cascades (Chao and Nestler, 2004; Snyder and 2 
Gao, 2013; Yuan et al., 2010). A clinical study has identified novel variants in the 3 
CREB gene in schizophrenic patients who experienced the positive symptoms of 4 
schizophrenia (Kawanishi et al., 1999). CREB is a member of the basic leucine zipper 5 
domain (bZIP) super family of transcription factors. It has a C-terminal zipper domain 6 
that is responsible for binding to 11 DNA and a leucine zipper domain that controls 7 
dimerisation with itself or transcription factors in the CREB family (Chao and Nestler, 8 
2004). CREB dimers bind to consensus cAMP response element (CREs), regulating 9 
transcription of downstream genes. Many genes have CREs in their promoters including 10 
genes coding for neuropeptides, neurotransmitter synthesizing enzymes, 11 
neurotransmitter receptors, signalling proteins, and other transcription factors. These 12 
CRE-mediated transcription responses require phosphorylation of CREB.  13 
 14 
CREB activity is reported to have been altered by various antipsychotic ligands in both 15 
in vitro and in vivo studies. An in vitro study has demonstrated that amisulpride, but not 16 
haloperidol, induced phosphorylation of CREB via the Akt-GSK3β pathway in the SH-17 
SY5Y cells (Park et al., 2011b). In addition, both amisulpride and clozapine increased 18 
CREB phosphorylation in both SH-SY5Y and U87 cells (Jeon et al., 2015). It has also 19 
been reported that a 25-day administration of haloperidol and risperidone increased 20 
phosphorylation of CREB in hippocampal neurons (Yang et al., 2004). In animals, both 21 
amphetamine and haloperidol were able to activate CREB in the rat striatum (Hsieh et 22 
al., 2002; Konradi et al., 1994; Konradi and Heckers, 1995). Pozzi et al. (2003) have 23 
found that haloperidol and a D2R antagonist – eticlopride – stimulated phosphorylation 24 
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acute administration of olanzapine produced dose-dependent decreases in the 1 
phosphorylation of CREB in a rat PFC, but not in the striatum, while haloperidol did not 2 
have such an effect in either brain region (Turalba et al., 2004). Lastly, a 3-week 3 
injection of aripiprazole induced increased CREB phosphorylation  in the PFC and 4 
striatum of rats, probably through glutamatergic NMDA receptors (Mavrikaki et al., 5 
2014). However, this study examined CREB in the whole striatum, not differentiating 6 
between the CPu or NAc. Since CPu and NAc play different roles in the 7 
pathophysiology of schizophrenia and actions of antipsychotics, it is important to study 8 
the different effects of antipsychotics on CREB in the CPu and NAc. It is also worth 9 
investigating the effects of long-term administration of antipsychotics on CREB in these 10 
brain regions. 11 
 12 
2.5 Rationales, aims and hypotheses 13 
2.5.1 Rationales of this thesis 14 
As already reviewed, aripiprazole has therapeutic effects on both positive and negative 15 
symptoms of schizophrenia, but induces EPS at a lower rate compared with typical 16 
antipsychotics. The D2R partial agonism has been attributed as the unique clinical 17 
profile of aripiprazole by many researchers. However, except aripiprazole, all other D2R 18 
partial agonists have been abandoned in clinical trials. They either did not achieve 19 
meaningful therapeutic effects or induced severe side-effects. Therefore, the 20 
contribution of D2R partial agonism to the molecular mechanism of aripiprazole 21 
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The dopamine systems play a key role in the pathophysiology of schizophrenia. There 1 
are three major dopaminergic pathways that are involved in schizophrenia and the 2 
action of antipsychotics. A previous study of our group demonstrated that aripiprazole 3 
differentially affected mesolimbic and nigrostriatal dopaminergic transmission by 4 
examining dopamine synthesis and D2R binding (Han et al., 2009). However, how 5 
aripiprazole affects the downstream signalling of D2R in a brain-regional dependent 6 
manner is yet to be revealed. 7 
 8 
There are two major downstream signalling pathways of D2R – the PKA signalling 9 
pathway and Akt-GSK3 signalling pathway. These two signalling pathways are also 10 
involved in the regulation of several other substrates and receptors (i.e. β-catenin, 11 
GABAA receptors and CREB1). A range of previous studies have shown that PKA and 12 
Akt-GSK3 signalling as well as their downstream regulators can be affected by 13 
administration of various antipsychotic drugs, as reviewed before. However, the effects 14 
of aripiprazole on these cellular signalling pathways has not been systematically 15 
examined and compared with other antipsychotics.  16 
 17 
As stated above, it is, therefore, important to determine the molecular mechanisms 18 
underlying the actions of aripiprazole using our established rat model (De Santis et al., 19 
2014; Han et al., 2009). Bifeprunox (a D2R partial agonist) and haloperidol (a D2R 20 
antagonist) will be used as reference drugs for comparison. Additionally, it has been 21 
proposed that positive, negative and cognitive symptoms of schizophrenia are 22 
associated with dysfunction of different brain regions (Buckley, 2005). Therefore, it is 23 
necessary to investigate any brain regional differences between the actions of 24 
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under clinical conditions, patients always experience long-term antipsychotic treatment. 1 
Therefore, it is critical to investigate the effects of not only acute/short-term, but also 2 
chronic, administration of these antipsychotics on the cellular signalling pathways. 3 
 4 
2.5.2 Aims 5 
The general aim of this study is to understand the molecular mechanism of aripiprazole 6 
in the key brain regions that are related to the actions of antipsychotics by investigating 7 
the effects of aripiprazole on various cellular signalling pathways in an established 8 
animal model.  9 
 10 
The specific aims of this research were to: 11 
1. Investigate whether acute administration of aripiprazole differentially affects D2R-12 
mediated downstream signalling pathways in the key brain regions that are related 13 
to the action of antipsychotics, in comparison with bifeprunox and haloperidol. 14 
 15 
2. Examine the effects of aripiprazole on the D2R-related signalling pathways, as well 16 
as their potential regulation of GABAA receptors and CREB, in comparison with 17 
bifeprunox and haloperidol. 18 
 19 
3. Reveal the effects of long-term administration of aripiprazole on the D2R-related 20 
signalling pathways, as well as their potential regulation on GABAA receptors and 21 
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2.5.3 Hypotheses 1 
1. Acute administration of aripiprazole differentially affects PKA and GSK3β activity, 2 
in comparison with bifeprunox and haloperidol. (Chapter 3) 3 
 4 
2. Short-term administration of aripiprazole has different effects on PKA, GABAA 5 
(containing β-1 subunit) receptors and CREB in the NAc, in comparison with 6 
bifeprunox and haloperidol. (Chapter 4) 7 
 8 
3. Short-term 1-week administration of aripiprazole differentially affects the Akt-9 
GSK3β and Dvl-3-GSK3β-β-catenin signalling pathways in various brain regions, 10 
in comparison with bifeprunox and haloperidol. (Chapter 5) 11 
 12 
4. Long-term 10-week administration of aripiprazole has different effects on PKA 13 
signalling, Akt-GSK3β signalling, Dvl-GSK3β-β-catenin signalling, GABAA 14 
(containing β-1 subunit) receptors and CREB activity in the PFC, CPu and NAc, in 15 
comparison with bifeprunox and haloperidol. (Chapter 6) 16 
 17 
Overall, in the thesis, all the above hypotheses were tested in the established animal 18 
model for the oral administration of antipsychotics (De Santis et al., 2014; Han et al., 19 









CHAPTER 3   UNIQUE EFFECTS OF ACUTE ARIPIPRAZOLE 4 
TREATMENT ON THE DOPAMINE D2 RECEPTOR DOWNSTREAM CAMP-5 
PKA AND AKT-GSK3Β SIGNALLING PATHWAYS IN RATS 6 
 7 
Published in PLoS One 10, e0132722. DOI: 10.1371/journal.pone.0132722. Pan, B., 8 
Chen, J., Lian, J., Huang, X.F., and Deng, C. (2015). Unique effects of acute 9 
aripiprazole treatment on the dopamine D2 receptor downstream cAMP-PKA and Akt-10 
GSK3β signalling pathways in rats, © 2015 Pan et al. under the Creative Commons 11 
Attribution (CC BY) license.  12 
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Aripiprazole is a wide-used antipsychotic drug with therapeutic effects on both positive and
negative symptoms of schizophrenia, and reduced side-effects. Although aripiprazole was
developed as a dopamine D2 receptor (D2R) partial agonist, all other D2R partial agonists
that aimed to mimic aripiprazole failed to exert therapeutic effects in clinic. The present in
vivo study aimed to investigate the effects of aripiprazole on the D2R downstream cAMP-
PKA and Akt-GSK3β signalling pathways in comparison with a D2R antagonist – haloperi-
dol and a D2R partial agonist – bifeprunox. Rats were injected once with aripiprazole
(0.75mg/kg, i.p.), bifeprunox (0.8mg/kg, i.p.), haloperidol (0.1mg/kg, i.p.) or vehicle. Five
brain regions – the prefrontal cortex (PFC), nucleus accumbens (NAc), caudate putamen
(CPu), ventral tegmental area (VTA) and substantia nigra (SN) were collected. The protein
levels of PKA, Akt and GSK3β were measured by Western Blotting; the cAMP levels were
examined by ELISA tests. The results showed that aripiprazole presented similar acute
effects on PKA expression to haloperidol, but not bifeprunox, in the CPU and VTA. Addition-
ally, aripiprazole was able to increase the phosphorylation of GSK3β in the PFC, NAc, CPu
and SN, respectively, which cannot be achieved by bifeprunox and haloperidol. These
results suggested that acute treatment of aripiprazole had differential effects on the cAMP-
PKA and Akt-GSK3β signalling pathways from haloperidol and bifeprunox in these brain
areas. This study further indicated that, by comparison with bifeprunox, the unique pharma-
cological profile of aripiprazole may be attributed to the relatively lower intrinsic activity at
D2R.
Introduction
Aripiprazole has therapeutic effects on both positive and negative symptoms of schizophrenia,
with improved extrapyramidal side-effects (EPS) compared with first-generation antipsychotic
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drugs (e.g. haloperidol) and reduced metabolic side-effects compared with second-generation
antipsychotic drugs (e.g. olanzapine); aripiprazole is regarded as the third-generation antipsy-
chotic drug [1, 2]. The exact mechanisms of aripiprazole remain unclear. Several studies sug-
gested that the potent partial agonism of aripiprazole for the dopamine D2 receptor (D2R)
stabilises the dopamine D2 system, playing a critical role in its unique clinical actions [3, 4].
However, this hypothesis has been questioned because there are no other D2R partial agonists
that are widely accepted and used after aripiprazole. On the other hand, a theory called func-
tional selectivity has been postulated to explain the pharmacological profile of aripiprazole [1].
The theory of functional selectivity suggests that depending on the cellular location and envi-
ronment of the target G protein-coupled receptors (GPCRs), some ligands (drugs) can induce
distinct conformations of GPCRs, resulting in differential regulation of canonical and non-
canonical signal transduction pathways associated with these GPCRs [5–7]. Accumulated evi-
dence from in vitro studies suggested that aripiprazole displays functional selectivity on D2R; it
may act as a potent partial agonist, weak agonist, or antagonist depending on the targeted D2Rs
[1, 4, 6, 8–10]. An in vivo study from our group found selective effects of aripiprazole on the
mesolimbic vs. the nigrostriatal dopaminergic pathways compared with haloperidol, which
could be explained by the functional selectivity of aripiprazole [11]. However, how aripiprazole
differentially affects the downstream signalling pathways of the D2R in various dopaminergic
pathways in vivo has not been well studied.
Two major D2R downstream cellular signalling pathways have been identified. The canoni-
cal transduction pathway is the G protein-dependent cyclic adenosine monophosphate
(cAMP)-protein kinase A (PKA) pathway, which mediates various cellular responses such as
proliferation, metabolism and gene transcription [12–14]. Blockade of D2R in the brain is asso-
ciated with the pharmacological properties of all antipsychotic drugs, including the therapeutic
effects and some side-effects (e.g. EPS side-effects) [15]. However, whether and how D2R-
mediated PKA signalling is involved in these pharmacological properties is not clear. There-
fore, unveiling the effects of aripiprazole on the PKA signalling in various brain regions might
elucidate the mechanism of aripiprazole and provide a new route for the development of
improved antipsychotics. Furthermore, previous evidence suggested that D2-like dopamine
autoreceptors have a preferential coupling to the PKA pathway to control dopamine synthesis
[16, 17], release [18, 19] and uptake [20, 21]. However, previous studies showed discrepant
influences of antipsychotic drugs on dopamine synthesis capacity. Acute treatment with halo-
peridol and aripiprazole both increased dopamine synthesis while quinpirole (a D2R agonist)
reduced it in the caudate putamen (CPu) in rodents [22]. Additionally, acute administration
with haloperidol in healthy human subjects induced a significant increase in dopamine synthe-
sis capacity in various brain regions, including the striatum, mesencephalon, and medial pre-
frontal cortex (PFC) [23]. An in vivo study from our group demonstrated that aripiprazole
down-regulated tyrosine hydroxylase (TH) mRNA expression in the ventral tegmental area
(VTA), but not in the substantia nigra (SN), indicating reduced dopamine synthesis capacity
after 1-week and 12-week treatment [11]. Therefore, the present study further investigated the
relationship between the PKA activity and the TH activity after acute antipsychotic treatment.
Besides the canonical G protein-dependent cAMP-PKA signalling pathway, the non-
canonical D2R transduction pathway is the G protein-independent protein kinase B (PKB/
Akt)-glycogen synthase kinase 3 (GSK3) pathway. Studies implicated Akt and GSK3β signal-
ling in the pathophysiology of neuropsychiatric disorders such as schizophrenia, bipolar dis-
order, and depression [24–26]. Studies on patients with schizophrenia showed decreased
phosphorylation levels and GSK3 protein levels in the PFC [27–29]. In animal studies, GSK3β
activity was elevated in the striatum, in a D2R- and β-arrestin2-dependent manner, under
hyperdopaminergic conditions [24, 30–32]. An animal behavioural study comparing
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aripiprazole with β-arrestin2-biased D2R ligands also suggested that the β-arrestin2 signalling
cascade can be simultaneously a significant contributor to antipsychotic therapeutic effects
and a protective effect against motor side-effects [33]. Based on these findings, we proposed
that aripiprazole might exert its therapeutic effects and reduced EPS side-effects via D2R-
dependent Akt-GSK3β signalling.
Therefore, the present study examined the in vivo effects of aripiprazole on the cAMP-PKA
and Akt-GSK3β signalling pathways in the mesolimbic, mesocortical and nigrostriatal dopami-
nergic pathways in comparison with a potent D2R antagonist—haloperidol and a D2R partial
agonist—bifeprunox.
Methods
Animals and drug treatment
Male Sprague Dawley rats (aged 8 weeks) were obtained from the Animal Resource Centre
(Perth, Australia). After arrival, all rats were divided into four treatment groups (n = 6/group).
Rats were housed in individual cages under environmentally controlled conditions (tempera-
ture 22°C, light cycle from 07:00 to 19:00 h), with ad libitum access to water and standard labo-
ratory chow diet. After 1-week acclimatisation to the new surroundings, all rats were injected
with aripiprazole (0.75mg/kg, intraperitoneal (i.p.)), haloperidol (0.1mg/kg, i.p.), bifeprunox
(0.8mg/kg, i.p.) or vehicle, respectively. All drugs were suspended in a 10% hydroxypropyl-β-
cyclodextrin (Sigma, St. Louis, MO) solution. The dosages used in the present study were
equivalent to the recommended dosage for treating schizophrenia patients, and calculated
based on body surface area according to the FDA guidelines for clinical trials [34, 35]. Rats
were euthanised by using carbon dioxide 2 hours after injection. This time-pointed was deter-
mined because all of the three drugs were rapidly absorbed after administration. For example,
the plasma levels of haloperidol reached the maximum at 1 hour after oral and intramuscular
administration in rats [36], while the aripiprazole concentration reached 80% of peak level in
plasma and brain of rats at 1 hour after oral administration [37]. Although no pharmacokinetic
data of bifeprunox were found in rats, a human study reported that bifeprunox reached peak
plasma concentration within 1.5 hours after oral administration [38]. Brains were collected
and then stored at -80°C. All rats were sacrificed between 10:00 A.M. and 12:00 A.M. to mini-
mise possible circadian-induced variation of protein expression.
Ethics Statement
All experimental procedures were approved by the Animal Ethics Committee (Application #:
AE11/02), University of Wollongong, and complied with the Australian Code of Practice for
the Care and Use of Animals for Scientific Purposes (2004). All animals were euthanised by
using carbon dioxide. All efforts were made to minimise animal distress and prevent suffering.
Microdissection
Following a standard procedure used in our lab, discrete brain regions were collected by using
brain microdissection puncture [39–41]. Briefly, 500μm thickness fresh frozen brains were cut
at -14°C and collected on glass slides. Based on the rat brain atlas [42], three sections through
the forebrain (Bregma 3.30 to 4.20mm) were collected for microdissection of the PFC. Three
sections through the striatum (Bregma 1.00 to 2.20mm) were collected for microdissection of
the nucleus accumbens (NAc) and CPu. Three sections through the midbrain (Bregma -5.40 to
-6.30mm) were collected for microdissection of the VTA and SN. For the PFC, NAc and CPu,
bilateral punches (1.2mm) were collected from each of the three sections. For the VTA, each of
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the bilateral punches (0.8mm) was taken at a region medial to the medial lemniscus and dorsal
to the interpeduncular nucleus. For the SN, each of the bilateral punches (0.5mm) was directed
to the lateral border of the medial lemniscus. Tissue punches from each region were collected
in microfuge tubes chilled on dry ice and kept frozen for future use.
Western blot analyses
Tissue obtained from individual rat was homogenised and the supernatants were collected and
stored at -80°C until required. Protein concentrations were determined spectrophotometrically
at A750nm using the DC Protein Assay (Bio-Rad, #500–0111). Samples containing 10 μg of
protein were resolved by 10% SDS–PAGE gels, and then transferred electrophoretically to a
polyvinylidene difluoride (PVDF) membrane by using Bio-Rad Midi Format 1-D Electropho-
resis Systems. The PVDF membranes were blocked for 1 hour at room temperature in Tris-
buffered saline-Tween (TBST) containing 5% BSA, and incubated overnight at 4°C in primary
antibodies diluted in TBST containing 1% BSA. Luminata Western horseradish peroxidase
(HRP) Substrates (Millipore) and Kodak XBT-1 film were used to examine the membrane to
visualise the immunoreactive bands. The immunoreactive signals were quantified using Bio-
Rad Quantity One software. The data were then corrected based on their corresponding actin
levels. All results were normalised by taking the value of the vehicle group as 100%. Experi-
ments were performed in duplicate.
Four regulatory (RIα, RIIα, RIβ, and RIIβ) and two catalytic (Cα and Cβ) isoform genes
have been identified previously [43]. PKA-RII expression is highest in brain tissues; PKA Cα
and PKA Cβ are closely related (93% amino acid sequence similarity), PKA-Cα is ubiquitously
expressed, and expression of PKA-Cβ is also highest in the brain [44–47]. Four antibodies for
PKA subunits were chosen in the present study: PKA-RIIα (1:1000; Santa Cruz, #SC-908),
PKA-Cα (1:1000; Cell Signalling, #5842), PKA-Cβ (1:1000; Santa Cruz, #SC-904) and phos-
pho-PKA-C (Thr197) (1:1000; Cell Signalling, #5661). For the Akt-GSK3 pathway, the primary
antibodies include: Akt (1:2000; Cell Signalling, #4691), phospho-Akt (Thr308) (1:1000; Cell
Signalling, #13038), GSK3β (1:2000; Cell Signalling, #5676), and phospho-GSK3β (Ser9)
(1:1000; Cell Signalling, #9322). We also examined tyrosine hydroxylase (1:1000; Millipore,
#AB9983) and phospho-tyrosine hydroxylase (Ser40) (1:1000; Millipore #AB5935) in the VTA
and SN to test their influence on dopamine synthesis. Mouse anti-actin primary polyclonal
antibody (1:10000; Millipore, #MAB1501) and HRP-conjugated rabbit anti-mouse secondary
antibody (1:3000; Cell Signalling, #7076) were used to determine the actin levels.
cAMPmeasurement
The brain tissue was collected by microdissection described before, and assayed using a cAMP
Direct Immunoassay Kit (Abcam, #ab65355) according to the manufacturer’s instructions.
Briefly, the brain tissue was homogenised with 0.1M HCl, and centrifuged at 10,000g for 15
minutes at 4°C to obtain the supernatant. Then 100 μL of the diluted cAMP standard solution
(0.039, 0.078, 0.156, 0.3125, 0.625, 1.25, 2.5, 5, and 10pmol/μl) or 50μl of the supernatant
(added with 50μl 0.1M HCl) was mixed with kit reaction solution accordingly, and loaded to
96-well plates. All standards and samples were run in duplicate to ensure consistency of the
reading. The plates were then treated with cAMP antibody, cAMP-HRP and HRP Developer,
and measured spectrophotometrically at 450nm. The cAMP values obtained from the lumines-
cence measurements were converted by the total protein amount determined using the DC
Protein Assay (Bio-Rad, #500–0111) accordingly, expressed as picomole of cAMP per nano-
gram of protein.
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All data was analysed using the SPSS Statistics v19.0 program. The data of both western blot
analyses and cAMP measurement was normalised by taking the value of the control group as
100% and expressed as mean ± S.E.M. All phosphor proteins were also normalised to total pro-
tein levels. For example, p-PKA was normalised by the average levels of PKA-Cα and PKA-Cβ;
p-TH, p-Akt and p-GSK3β were normalised by the levels of total TH, Akt and GSK3β, respec-
tively. The Kolmogorov-Smirnov test was performed to test the normality of the data. One-
way ANOVA was used if the data was normally distributed, followed by Post Hoc Tukey test to
compare the control and drug treatment groups. Nonparametric Mann-Whiney U-test was
applied when data was abnormal distributed. Statistical significance was accepted when
p< 0.05.
Results and Statistical Analyses
The effects on the cAMP-PKA signalling pathway
PFC. ANOVA test did not identify any significant effects in the protein levels of PKA-Cα,
PKA-Cβ, PKA-RII and p-PKA or the ratio of p-PKA/PKA after all three drug treatment in the
PFC (Fig 1A and Fig 2A).
NAc. The levels of p-PKA in the NAc were shown to be significantly affected by drug
treatment (F3, 22 = 11.157, p< 0.001); however, the ratio of p-PKA/PKA was also not signifi-
cantly affected by drug treatment (F3, 22 = 1.390, p> 0.05). The protein levels of PKA-Cα, -Cβ,
and-RII subunits did not change after drug treatment. Post Hoc analysis identified that only
treatment with bifeprunox, not aripiprazole and haloperidol, enhanced the activity of the p-
PKA subunit (+66.3%, p< 0.05) (Fig 1B).
CPu. ANOVA test revealed significant effects of drug treatment on the expression of
PKA-Cα (F3, 23 = 11.806, p< 0.001), PKA-Cβ (F3, 23 = 4.985, p = 0.011) and PKA-RII (F3, 21 =
7.041, p = 0.002), but not p-PKA; however, the ratio of p-PKA/PKA was significantly changed
by drug treatment (F3, 23 = 13.687, p< 0.001). Post Hoc analysis showed that both aripiprazole
(p< 0.01) and haloperidol (p< 0.01) significantly elevated the expression of PKA-Cα, by
33.1% and 34.6%, respectively; only treatment with bifeprunox significantly increased the
expression of the PKA-Cβ subunit by 31.9% (p< 0.05) (Fig 1C). Additionally, haloperidol
treatment negatively affected expression of the PKA-RII subunit (-34.0%, p< 0.01). Moreover,
both aripiprazole and haloperidol had no effects on the protein levels of PKA-Cβ; and bifepru-
nox did not alter the protein levels of PKA-Cα, and-RII subunits. The ratio of p-PKA/PKA was
observed to be decreased by treatment with bifeprunox (p< 0.01), but increased by haloperidol
treatment (p< 0.05); aripiprazole did not affect the ratio of p-PKA/PKA (Fig 2C).
VTA. The expression of PKA-Cα (F3, 23 = 3.757, p = 0.027), PKA-Cβ (F3, 22 = 5.079,
p = 0.009) and PKA-RII (F3, 23 = 3.698, p = 0.029) has been significantly affected by drug treat-
ment in the VTA. The ratio of p-PKA/PKA was also changed by drug treatment (F3, 23 = 3.197,
p = 0.046), although the levels of p-PKA was not significantly altered (all p> 0.05). Post Hoc
analysis demonstrated that the expression of both PKA-Cα and PKA-Cβ subunit was signifi-
cantly increased by 20.9% and 49.4% by aripiprazole (p< 0.05) and bifeprunox (p< 0.01)
treatment, respectively (Fig 3A). We also observed that bifeprunox treatment significantly
reduced the ratio of p-PKA/PKA (p< 0.05) (Fig 4A). Additionally, treatment with haloperidol
significantly elevated the expression of the PKA-RII subunit by 41% (p< 0.05). Furthermore,
the levels of both TH and p-TH were showed to be increased by bifeprunox treatment, but not
significantly (TH, +50.7%, p> 0.1; p-TH, +34.0%, p> 0.1); aripiprazole and haloperidol did
not cause any noticeable change in the levels of TH and p-TH.
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Fig 1. The alterations in the PKA signalling in the prefrontal cortex, nucleus accumbens and caudate
putamen. The acute effects of three chemicals (aripiprazole, bifeprunox and haloperidol) on the protein
levels of three PKA subunits (PKA-Cα,-Cβ, and-RII) and phospho-PKA in the prefrontal cortex (A), nucleus
accumbens (B) and caudate putamen (C). (* p < 0.05, ** p < 0.01 vs. the control)
doi:10.1371/journal.pone.0132722.g001
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SN. ANOVA analysis identified significant effects of drug treatment on the levels of p-
PKA (F3, 19 = 6.956, p = 0.003) drug treatment; however, Post Hoc analysis did not reveal any
significant effects induced by any drug treatment (all p> 0.1) (Fig 3B). Additionally, the levels
of PKA subunits, TH and p-TH were not altered by any drug treatment in the SN. The ratio of
either p-PKA/PKA or p-TH/TH was not altered by any drug treatment (Fig 4B).
Measurement of cAMP. ANOVA analysis indicated significant effects on cAMP levels
only in the PFC (F3, 21 = 3.529, p = 0.036). Post Hoc analysis identified that only bifeprunox
Fig 2. The ratios of p-Akt/Akt, p-GSK3β/GSK3β and p-PKA/PKA in the prefrontal cortex, nucleus
accumbens and caudate putamen. The acute effects of three chemicals (aripiprazole, bifeprunox and
haloperidol) on the ratios of p-Akt/Akt, p-GSK3β/GSK3β and p-PKA/PKA in the prefrontal cortex, nucleus
accumbens and caudate putamen (* p < 0.05 vs. control; ** p < 0.01 vs. control).
doi:10.1371/journal.pone.0132722.g002
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significantly reduced the cAMP levels in the PFC (-53.3%, p< 0.05). There were no other nota-
ble changes in the cAMP levels in other four brain regions (all p> 0.05, Table 1).
The effects on the Akt-GSK3β pathway
PFC. In the Akt-GSK3β signalling pathway, the levels of p-GSK3β was significantly influ-
enced by drug treatment (F3, 21 = 7.504, p = 0.002) in the PFC; the ratio of p- GSK3β/GSK3β
has also been significantly affected (F3, 21 = 10.435, p< 0.001). Post Hoc analysis indicated that
only aripiprazole treatment, not haloperidol or bifeprunox treatment, significantly promoted
the levels of p-GSK3β (+31.3%, p< 0.05) (Fig 5A). Aripiprazole also increased the ratio of p-
GSK3β/GSK3β (p< 0.01) (Fig 2A).
NAc. ANOVA analysis showed that the levels of p-GSK3β were significantly affected by
drug treatment (F3, 23 = 9.161, p = 0.001) in the NAc; ANOVA tests also revealed that drug
treatment tended to significantly changed the ratio of p-GSK3β/GSK3β (F3, 23 = 2.585,
p = 0.082). Post Hoc test revealed that the levels of p-GSK3β were significantly increased by
both aripiprazole (p< 0.05) and haloperidol (p< 0.05), by 41.5% and 43.5%, respectively,
whereas bifeprunox had no such effect (Fig 5B). In addition, the ratio of p-GSK3β/GSK3β was
Fig 3. The alterations in the PKA signalling in the ventral tegmental area and substantia nigra. The acute effects of three chemicals (aripiprazole,
bifeprunox and haloperidol) on the levels of three PKA subunits (PKA-Cα, -Cβ, and-RII), phospho-PKA, TH and phospho-PH in the ventral tegmental area (A)
and substantia nigra (B). (* p < 0.05, ** p < 0.01 vs. the control)
doi:10.1371/journal.pone.0132722.g003
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significantly increased by treatment with aripiprazole (p< 0.05); haloperidol treatment also
tended to increase the ratio of p-GSK3β/GSK3β (p = 0.062) (Fig 2B).
CPu. Only the levels of p-GSK3β were shown to be significantly influenced (F3, 22 = 19.320,
p< 0.001) by drug treatment in the CPu; the ratio of p-GSK3β/GSK3β was also significantly
affected (F3, 22 = 17.103, p< 0.001). Post Hoc test identified significant enhancement on the lev-
els of p-GSK3β induced by aripiprazole (+58.3%, p< 0.05) and bifeprunox (+60.6%, p< 0.05)
treatment, respectively (Fig 5B). No drug treatment significantly influenced the levels of p-Akt,
Fig 4. The ratios of p-Akt/Akt, p-GSK3β/GSK3β, p-PKA/PKA and p-TH/TH in the ventral tegmental area
and substantia nigra. The acute effects of three chemicals (aripiprazole, bifeprunox and haloperidol) on the
ratios of p-Akt/Akt, p-GSK3β/GSK3β, p-PKA/PKA and p-TH/TH in the ventral tegmental area and substantia
nigra (* p < 0.05 vs. control; ** p < 0.01 vs. control).
doi:10.1371/journal.pone.0132722.g004
Table 1. The cAMP levels (pmol/ng protein; mean values ± SEM; n = 6/group) in five brain regions after acute antipsychotic treatment.
PFC NAc CPu VTA SN
Aripiprazole 75.0±16.6 55.0±7.9 34.3±7.5 166.7±32.7 85.0±13.3
Bifeprunox 49.0±7.4* 54.2±4.4 41.4±8.1 106.0±14.4 90.3±18.3
Haloperidol 74.8±15.2 58.9±3.2 40.7±3.5 115.8±8.3 132.5±22.5
Control 105.0±5.7 60.4±5.4 34.5±5.5 123.9±14.8 99.2±13.2
* p < 0.05
Abbreviations: CPu, caudate putamen; NAc, nucleus accumbens; PFC, prefrontal cortex; SN, substantia nigra; VTA, ventral tegmental area.
doi:10.1371/journal.pone.0132722.t001
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Fig 5. The alterations in the Akt-GSK3β in the prefrontal cortex, nucleus accumbens and caudate
putamen. The acute effects of three chemicals (aripiprazole, bifeprunox and haloperidol) on the levels of Akt,
phospho-Akt, GSK3β and phospho-GSK3β in the prefrontal cortex (A), nucleus accumbens (B) and caudate
putamen (C). (* p < 0.05 vs. the control)
doi:10.1371/journal.pone.0132722.g005
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total Akt or total GSK3β. Furthermore, both aripiprazole and bifeprunox treatment significantly
increased the ratio of p-GSK3β/GSK3β (aripiprazole, p< 0.01; bifeprunox, p< 0.05) (Fig 2C).
VTA. ANOVA analysis identified that only the levels of p-GSK3β in the Akt-GSK3β sig-
nalling pathway were significantly affected (F3, 22 = 7.124, p = 0.002) by drug treatment in the
VTA; the ratio of p-GSK3β/GSK3β was also significantly changed (F3, 22 = 7.015, p = 0.002).
Post Hoc test indicated a significant elevation in the expression of p-GSK3β after bifeprunox
treatment (+47.8%, p< 0.05) (Fig 6A); the ratio of p-GSK3β/GSK3β was also significantly
increased by bifeprunox (p< 0.01) (Fig 4A); no other significant result was observed.
SN. ANOVA test identified significant effects of drug treatment on the levels of p-Akt (F3,
21 = 4.243, p = 0.020) and the ratio of p-Akt/Akt (F3, 21 = 4.243, p = 0.020) in the SN; ANOVA
analysis also indicated a trend towards significance on the levels of p-GSK3β (F3, 20 = 2.946,
p = 0.061). Post Hoc analysis revealed that all three drugs significantly increased the levels of p-
Akt (aripiprazole, +23.9%, p< 0.05; bifeprunox, +37.6%, p< 0.05; haloperidol, +40.3%, p<
0.05) (Fig 6B); they all elevated the ratio of p-Akt/Akt (aripiprazole, p< 0.05; bifeprunox,
p< 0.01; haloperidol, p< 0.05) (Fig 4B). Additionally, only aripiprazole treatment significantly
Fig 6. The alterations in the Akt-GSK3β in the ventral tegmental area and substantia nigra. The acute
effects of three chemicals (aripiprazole, bifeprunox and haloperidol) on the levels of Akt, phospho-Akt,
GSK3β and phospho-GSK3β in the ventral tegmental area (A) and substantia nigra (B). (* p < 0.05 vs. the
control)
doi:10.1371/journal.pone.0132722.g006
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raised the levels of p-GSK3β by 33.0% (p< 0.05), but it did not significantly influence the ratio
of p-GSK3β/GSK3β (p> 0.05).
Discussion
The present study demonstrated the in vivo effects of aripiprazole on the downstream pathways
of the D2R, by comparing it with haloperidol and bifeprunox. The results of the current study
showed that aripiprazole had similar effects on PKA subunits to haloperidol, but not bifepru-
nox in the CPu and VTA, indicating that relatively lower intrinsic activity of aripiprazole on
D2R might be the mechanism of aripiprazole to exert its therapeutic effects on treating positive
symptoms of schizophrenia; on the other hand, aripiprazole displayed a very different action
mode on the GSK3β activity from the other two chemicals, probably explaining its therapeutic
effects on both positive and negative symptoms of schizophrenia, with reduced EPS. Together,
these in vivo findings suggest that the relatively low intrinsic activity at D2R might be the rea-
son that aripiprazole possesses unique pharmacological profiles and clinical effects from the
other antipsychotic drugs.
Antipsychotic effects on PKA signalling and TH activity
Dopamine is largely synthesised in the VTA and SN, and transported to the synapses in the
PFC, CPu and NAc [48–51]. In the VTA and SN, short-form dopamine D2 autoreceptors are
largely presented at pre-synapses, which generally provide a feedback mechanism that adjusts
neuronal firing rate, dopamine synthesis capacity, and dopamine release in response to changes
in extracellular dopamine level [52–54]. The G protein-dependent PKA signalling pathway is a
canonical D2R downstream signalling pathway which mediates diverse cellular responses to
external responses by activating the cAMP-dependent protein kinase including PKA kinase
[12–14]. By reaction with cAMP, the inactive PKA could release a dimer of regulatory subunits,
and two free monomeric catalytic subunits that can further phosphorylate other protein sub-
strates [55]. It is suggested that the inhibition of the PKA transduction pathway induced by
activation of D2 autoreceptors leads to reduced TH activity and decreased firing of dopamine
neurons both in vivo and in vitro [56, 57]. In the present study, we observed that all three anti-
psychotics were able to differentially affect the expression of PKA subunits in various brain
regions, as well as TH levels (although some results did not reach significance). For example,
aripiprazole significantly increased the expression of PKA-Cα and PKA-RII subunits, and bife-
prunox and haloperidol also significantly elevated the levels of PKA-Cβ and PKA-RII, respec-
tively. In view of acute (2 hours) treatment, it is possible that these drugs may modulate
protein expression of PKA subunits through affecting the actively translatable pool of mRNA,
although further studies are necessary to confirm it. Moreover, aripiprazole reduced (not
reaching significance) the expression of TH, while bifeprunox increased it (not significantly) in
the VTA, which suggests that aripiprazole might potentially exert a different effect from that of
bifeprunox and haloperidol on dopamine synthesis capacity. However, there were inconsistent
reports about the effect of antipsychotics on dopamine synthesis capacity. For example, acute
treatment with haloperidol and aripiprazole both increased dopamine synthesis while quinpir-
ole (a D2R agonist) reduced it in rats CPu [22], although aripiprazole with agonistic activity at
pre-synaptic D2 autoreceptors might reduce dopamine synthesis through feedback regulation
[10, 58]. Moreover, acute administration with haloperidol in healthy human subjects induced a
significant increase in dopamine synthesis capacity in various brain regions, including the stri-
atum, mesencephalon, and medial PFC [23]. Our group using the same dosages of aripiprazole
found that both 1-week and 12-week treatment with aripiprazole reduced the dopamine syn-
thesis capacity in the VTA, but not in the SN [11]. The exact reason for the discrepancies
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between these studies remains unknown. One possible reason might be that the brain regions
examined in the literature are not completely concordant with those in this study, which indi-
cates that the effects of antipsychotics are quite brain-regional related; another possible reason
might be the treatment dosages and treatment periods. For example, Der-Ghazarian’s study
[22] used 10mg/kg for aripiprazole and 1mg/kg for haloperidol; these doses are considerably
larger than those used in this study and might be a non-physiological response. It is worth not-
ing that aripiprazole, in the present study, displayed different effects on the PKA pathway and
TH activity from those of bifeprunox and haloperidol in the VTA and SN (although some
changes did not reach significance), probably implying that D2R partial agonism or D2R antag-
onism cannot fully explain the unique pharmacological profile of aripiprazole. It is also worth
pointing out that since the mesolimbic dopaminergic pathway is hyper-activated in schizo-
phrenia, the increased dopamine synthesis capacity of bifeprunox in the VTA might partly
explain why it failed to exert therapeutic effects in treating schizophrenia. The present study
used only acute treatment, and we observed only some trends in the effects of antipsychotics
(especially on the TH activity), possibly because the treatment period was too short. Therefore,
experiments with longer treatment periods are required to confirm these findings.
In the PFC, CPu and NAc, long-form dopamine D2 receptors are highly expressed, regulat-
ing post-synaptic functions. Similar to the situation in the VTA and SN, these three drugs influ-
enced the expression of PKA subunits in different manners in the PFC, CPu and NAc. Previous
studies also suggested that aripiprazole inhibited cAMP accumulation and reduced PKA path-
way signalling due to its partial agonism for the D2R, while haloperidol increased cAMP levels
and facilitated its signalling [4, 8, 9, 59, 60]. Additionally, PKA-C levels were reported to be ele-
vated in the CPu 15 minutes after acute treatment with haloperidol, but not the PFC and NAc
[61]; the activity of the cAMP-PKA pathway in the striatum and protein levels of PKA-RII sub-
unit in the striatum were also significantly increased after chronic treatment (21 days) with hal-
operidol due to its antagonism for the D2R [62]. In the present study, we observed that
aripiprazole decreased PKA-Cα levels in the PFC, inhibiting PKA signalling, which is consistent
with previous studies. Interestingly, our study exhibited that both aripiprazole and haloperidol
affected PKA protein levels in a very similar pattern in the CPu and VTA; thereby, it is possible
that both aripiprazole and haloperidol display similar antagonising effects on post-synaptic
D2R in the CPu and VTA after acute treatment. Since aripiprazole is a D2R partial agonist, its
intrinsic activity of aripiprazole for D2R is lower than that of endogenous dopamine, which
might result in antagonising effects on D2R signalling; and this relatively low intrinsic activity
might be the reason why not all D2R partial agonists could have meaningful therapeutic effects
as aripiprazole. Lastly, only bifeprunox, a potent D2R partial agonist, was able to significantly
inhibit the cAMP levels in the PFC, indicating that agonism for the D2R in the PFC might not
contribute to the therapeutic effects of aripiprazole; hence, bifeprunox also displayed different
effects on the PKA activity from both aripiprazole and haloperidol in the present study, which
probably explains the failure of bifeprunox in clinic trials. The intrinsic activity might also play
a critical role in the different effects between bifeprunox and aripiprazole. The intrinsic activity
of bifeprunox for D2R is higher than that of aripiprazole [35]. At current dosage, the intrinsic
activity of bifeprunox might not be low enough to induce antagonising effects as aripiprazole,
although it is possible that the dosage of bifeprunox was insufficient to compete against endoge-
nous dopamine to exhibit antagonising effects. This point can be verified by their different alter-
ations in the ration of p-PKA/PKA in the CPu. The intrinsic activity of aripiprazole is neither
high enough to positively affect the ratio of p-PKA/PKA as bifeprunox, nor low enough to neg-
atively affect it as haloperidol. Since some D2R partial agonist with very low intrinsic activity
(e.g. SDZ 208–912) could induce side-effects like EPS [63], a moderate intrinsic activity for the
D2R might be a critical factor to develop optimum antipsychotics.
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Antipsychotic effects on the Akt-GSK3β signalling
In addition to the canonical G protein-dependent cAMP-PKA signalling pathway, the D2R sig-
nalling is also mediated by the Akt-GSK3β via β-arrestin2; many studies have indicated that
Akt-GSK3β signalling plays a critical role in the pathophysiology of schizophrenia [24, 25, 27,
64]. Post-mortem studies on schizophrenic subjects demonstrated reduced phosphorylation
levels and GSK3β protein levels in the PFC [28, 29]. In rodents, reduction of D2R- and β-arrest-
in2-dependent locomotor behaviours was observed in the situation of hyperactivity of GSK3β
[24, 30–32].
The effects of antipsychotic drugs on Akt-GSK3β signalling have also been confirmed by a
range of studies. In vivo studies indicated enhanced GSK3β phosphorylation in various brain
areas of rodents after various first- and second-generation antipsychotic treatment [65–68]. A
human study also suggested haloperidol treatment compensated for the decreased levels of
endogenous Akt in the PFC in schizophrenic subjects, phosphorylating GSK3β, and leading to
inhibition of its activity [69]. Collectively, antipsychotic drugs are capable of increasing the
phosphorylation of GSK3β, thus inducing inhibition of the GSK3β kinase. The present study
demonstrated that acute treatment with aripiprazole increased the levels of p-GSK3β, as well as
the ratio of p-GSK3β/GSK3β in the PFC, CPu, NAc, respectively, which indicates the inhibition
of the functions of GSK3β in these brain areas. On the other hand, bifeprunox elevated the lev-
els of p-Akt in the SN and p-GSK3β in the CPu and VTA, as well as the ratios, simultaneously.
Haloperidol reduced the activity of GSK3β by elevating the levels of p-GSK3β and the ratio of
p-GSK3β/GSK3β in the NAc as well as increased the phosphorylation of Akt in the SN, but hal-
operidol did not affect GSK3β levels.
Obviously, the three compounds displayed distinct effects on Akt-GSK3β in the current
study. Aripiprazole, in the present study, elevated the phosphorylation of GSK3β in the PFC,
NAc, CPu and SN, thus resulting in inhibition of the activity of GSK3β in these brain regions.
These findings suggested that aripiprazole probably exerted its therapeutic effects and reduced
EPS by affecting GSK3β. A previous study found that acute treatment with various second-gen-
eration antipsychotics (including olanzapine, risperidone, clozapine) facilitated the phosphory-
lation of GSK3β in the cortex, striatum and hippocampus [68]. Thus, together with our
findings, aripiprazole probably shares common mechanisms with other second-generation
antipsychotics to act on the GSK3β signalling to exert therapeutic effects. On the other hand,
bifeprunox had fewer effects on GSK3β than aripiprazole, especially in the PFC and NAc. The
reasons that aripiprazole and bifeprunox showed different effects on GSK3β signalling could be
their different intrinsic activities at D2R, however we could not completely exclude the possibil-
ity that the dosage of bifeprunox used in this study was insufficient to act on GSK3β signalling.
Haloperidol here displayed very limited effects on GSK3β, which might indicate that haloperi-
dol does not exert therapeutic effects via GSK3β signalling. Moreover, a previous study testing
animal behaviour after treating β-arrestin2-biased D2R ligands along with aripiprazole indi-
cated that activation of β-arrestin2 contributed to the protection against motor side-effects
[33]. Whether inhibition of GSK3β followed by activation of β-arrestin2 is directly linked to
this protective effect is not clear. However, our finding that aripiprazole, but not haloperidol,
reduced the activity of GSK3β in the CPu might provide an explanation. Lastly, it is worth not-
ing that the total levels of GSK3β did not change after acute treatment with all three com-
pounds, which is consistent with the findings of Alimohamad’s studies [65, 66].
It is clearly seen that the phosphorylation of GSK3β did not change completely in the same
manner as that of Akt in the present study. Two phosphorylating sites of Akt have been identi-
fied: Thr308 and Ser473, both of which can be affected by antipsychotics [24, 31, 32, 70]. In the
current study, the Thr308 site was examined since phospho-Thr308-Akt was indicated to be
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involved in the β-arrestin2/Akt/PP2A complex associated with D2R [31, 32], but not phospho-
Ser473-Akt. However, Akt with either of the sites phosphorylating can induce phosphorylation
of GSK3β at Ser9 that was examined in this study. Thus, it is very possible that the increased
levels of p-GSK3β in the present study might be induced by either phospho-Thr308- or phos-
pho-Ser473-Akt from different signalling pathways. Although an animal behavioural study
revealed that β-arrestin2-associated GSK3β signalling in D2R-expressing neurons is essential
for the antipsychotic effects of aripiprazole [71], the results of the present study suggested that
these drugs might affect the activities of GSK3β via multiple signalling pathways. In addition to
the modulation of the β-arrestin2-mediated signalling pathway, GSK3β is also involved in the
wingless (Wnt)-dishevelled-3 (Dvl3)-β-catenin signalling pathway [72]. Kang and Sutton
found that both haloperidol and clozapine regulate the activity of GSK3β through Wnt signal
pathways involving Dvl upstream in SH-SY5Y cells [73, 74]. In vivo studies indicated that halo-
peridol treatment significantly increased the phosphorylation of GSK3β at Ser9 in various
brain regions throughWnt-Dvl3-β-catenin signalling [65, 66]. Another report found that aripi-
prazole was also able to increase the phosphorylated GSK3β along with elevated β-catenin lev-
els in vivo [75]. Moreover, aripiprazole can also act at 5-HT1A receptors which also targets
GSK3β [76]. It has been reported that activation of 5-HT1A receptors led to increased phos-
phorylation of GSK3β in vivo [77]. Evidence also indicated that aripiprazole, at the same dose
as the present study, significantly increased 5-HT1A receptor binding density in vivo [78].
However, further studies are required to investigate whether 5-HT-regulated GSK3β signalling
is involved in the pharmacological properties of aripiprazole. Taken together, the results of the
present study suggested that regulation via β-arrestin2/Akt/PP2A signalling pathway by anti-
psychotics might partly contribute to the alterations in the activities of GSK3β; and the alter-
ations in the activities of GSK3β we observed in the present study might be an integrated
consequence of multiply signalling pathways regulated by antipsychotics.
Comparison between aripiprazole and haloperidol and bifeprunox
Aripiprazole vs. haloperidol. Haloperidol is a potent D2R antagonist [76], treating posi-
tive symptoms of schizophrenia effectively, but also inducing severe EPS. In the present study,
aripiprazole and haloperidol displayed, to some extent, similar effects on PKA signalling in the
mesolimbic dopaminergic pathway, indicating that aripiprazole might perform as an antago-
nist in the mesolimbic dopaminergic pathway within, at least, a few hours after treatment. In
contrast, aripiprazole showed much stronger effects on the levels of p-GSK3β in several brain
regions (e.g. PFC, NAc), probably elucidating haloperidol’s inability to treat negative symp-
toms of schizophrenia, since acute treatment with some other second-generation antipsychot-
ics were able to widely affect GSK3β [68]. Furthermore, since activation of β-arrestin2
contributes to the protective effects against motor side-effects [33], as discussed before, the
effects of aripiprazole in the CPu, compared with haloperidol, might reveal a connection
between the inhibition of GSK3β activity and reduced EPS.
Aripiprazole vs. bifeprunox. Bifeprunox is a D2R partial agonist that failed in clinic trials.
Some researchers have suggested that the therapeutic effects of aripiprazole are attributable to
its partial agonism at the D2R [79, 80]. In the present in vivo study, it is obvious that bifeprunox
affected both PKA and Akt-GSK3β transduction pathways and TH activity in a very different
manner from aripiprazole. The action mode of aripiprazole on GSK3β is more like that of the
second-generation antipsychotic drugs, not bifeprunox, probably due to a relatively lower
intrinsic activity of aripiprazole at D2R. However, we could not completely exclude the possi-
bility that the dosage of bifeprunox used in the present study was insufficient to induce antago-
nising effects on D2 receptors.
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In the present study, by comparison with haloperidol and bifeprunox, neither antagonism
nor partial agonism for the D2R could completely explain the unique activities of aripiprazole
on the D2R downstream signalling pathways. It is worth noting that functional selectivity has
been proposed to explain the unique pharmacological properties of aripiprazole [1]. Unfortu-
nately, no evidence in the present study can directly support the theory of functional selectivity
for aripiprazole. It is probably because the treatment in the present study was too short to take
effect; and the in vivo cellular environment is very complex and the activities of neurons in the
living brain are regulated by multiple and convergent factors. Therefore, long-term study and
more research methods are required to study this issue.
It is worth pointing out that acute antipsychotic treatment exerted very few or no effects on
the levels of p-PKA and cAMP levels in this study. Beaulieu et al. stated that within the first
30min after activation of D2R, G protein-coupled signalling induced a rapid and transient
change in the PKA transduction pathway, resulting in a short-term response; after 30min, the
Akt-GSK3 transduction pathway was activated, resulting in a more progressive and longer-last-
ing response [81]. In this study, we sacrificed animals 2 hours after drug administration. There-
fore, it is possible that the activation of the PKA signalling pathway had already diminished
when we sacrificed animals and collected brains.
There were also some limitations in the present study. It is worthy to note that the signalling
pathways examined in the present study were multi-targeted, and the drugs could react with
other dopamine receptors other than D2R. For example, the three compounds used in this
study have affinities with dopamine D3 receptors. Therefore, we cannot completely exclude the
effects of other dopamine receptors; further experiments are important to investigate the effects
of antipsychotics on these signalling pathways through specific subtypes of dopamine recep-
tors. Another limitation of the present study is that only the changes in the protein levels of the
signalling pathways were examined, further studies are necessary to examine the functional
and behavioural changes followed treatment of these antipsychotic drugs.
Conclusions
The present study demonstrated the various effects of acute treatment with aripiprazole, bife-
prunox and haloperidol on the two downstream signalling pathways of the D2R in five brain
regions. Our study revealed that acute treatment of aripiprazole had differential effects on both
cAMP-PKA and Akt-GSK3β signalling pathways from haloperidol and bifeprunox in various
brain areas. Furthermore, the differential acute effects of aripiprazole (compared with haloperi-
dol) on GSK3β signalling were also observed in the current study. Further studies in the effects
of chronic aripiprazole treatment on these signalling pathways in a schizophrenia animal
model might help to explain why aripiprazole has therapeutic effects on negative symptoms of
schizophrenia, along with reduced EPS. Our study also suggested that the unique pharmaco-
logical profile of aripiprazole might contribute to the relatively low intrinsic activity at the
dopamine D2 receptor. Further studies are required to explore the involvement of functional
selectivity theory in the mechanisms of aripiprazole.
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Abstract: Aripiprazole, a dopamine D2 receptor (D2R) partial agonist, possesses a unique clinical
profile. Glycogen synthase kinase 3  (GSK3 )-dependent signalling pathways have been implicated
in the pathophysiology of schizophrenia and antipsychotic drug actions. The present study examined
whether aripiprazole differentially affects the GSK3 -dependent signalling pathways in the prefrontal
cortex (PFC), nucleus accumbens (NAc), and caudate putamen (CPu), in comparison with haloperidol
(a D2R antagonist) and bifeprunox (a D2R partial agonist). Rats were orally administrated aripiprazole
(0.75 mg/kg), bifeprunox (0.8 mg/kg), haloperidol (0.1 mg/kg) or vehicle three times per day for
one week. The levels of protein kinase B (Akt), p-Akt, GSK3 , p-GSK3 , dishevelled (Dvl)-3,
and  -catenin were measured by Western Blots. Aripiprazole increased GSK3  phosphorylation
in the PFC and NAc, respectively, while haloperidol elevated it in the NAc only. However, Akt
activity was not changed by any of these drugs. Additionally, both aripiprazole and haloperidol,
but not bifeprunox, increased the expression of Dvl-3 and  -catenin in the NAc. The present study
suggests that activation of GSK3  phosphorylation in the PFC and NAc may be involved in the
clinical profile of aripiprazole; additionally, aripiprazole can increase GSK3  phosphorylation via
the Dvl-GSK3 - -catenin signalling pathway in the NAc, probably due to its relatively low intrinsic
activity at D2Rs.
Keywords: antipsychotics; aripiprazole;  -catenin; bifeprunox; Dvl-3; GSK3 ; haloperidol
1. Introduction
Aripiprazole is an atypical antipsychotic drug with therapeutic effects on both positive and
negative symptoms of schizophrenia, but reduced extrapyramidal side-effects (EPS) compared with
typical antipsychotics (e.g., haloperidol) [1]. The exact mechanisms of aripiprazole remain unclear.
Glycogen synthase kinase 3  (GSK3 ) has been implicated in the pathophysiology of schizophrenia
and the actions of antipsychotic drugs [2]. GSK3  is a major downstream regulator of dopamine D2
receptors (D2Rs), which is targeted by most antipsychotics (including aripiprazole) [3]. Activation
of D2Rs facilitates the formation of the  -arrestin2-protein phosphatase 2A-protein kinase B (PKB or
Akt) complex, resulting in dephosphorylation of Akt (inactivation), followed by dephosphorylation
(activation) of GSK3  [4–6]. Aripiprazole has been shown to have effects on regulating the Akt-GSK3 
signalling pathway [2]. For example, Seo et al. [7] have revealed that aripiprazole altered GSK3 
activity in the frontal cortex. However, whether aripiprazole can affect GSK3  activity in other
schizophrenia-related brain regions has not yet been studied. Our previous acute study [8] has
found that acute administration of aripiprazole increased the phosphorylation levels of GSK3  in
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various brain regions, including the prefrontal cortex (PFC), caudate putamen (CPu), and nucleus
accumbens (NAc). However, it is interesting that Akt did not show parallel changes with GSK3 
after acute administration [8]. One possibility is that aripiprazole might affect GSK3  activity
via alternative pathway(s) that is independent of Akt. One candidate pathway is the dishevelled
(Dvl)-GSK3 - -catenin signalling pathway. In vitro evidence has suggested that various antipsychotics
(e.g., clozapine, haloperidol) increase the cellular levels of Dvl and  -catenin via affecting D2Rs [9,10].
In vivo studies have reported that antipsychotic drug administration (including aripiprazole and
haloperidol) promoted phosphorylation of GSK3  and expression of Dvl and  -catenin in various
brain regions [10–14]. It has been also revealed that administration of aripiprazole attenuated the
decreased phosphorylation of GSK3  and reduced expression of  -catenin in the frontal cortex and
hippocampus caused by immobilisation stress [7,15]. It should be noted that all these previous
studies used intramuscular or subcutaneous injections to deliver aripiprazole. The effects of oral
administration that mimic the clinical situation is of importance. Therefore, in this study we examined
the Dvl-GSK3 - -catenin signalling pathway after sub-chronic oral administration of aripiprazole.
Aripiprazole is a D2R partial agonist. Researchers have attributed the unique clinical profile of
aripiprazole to its partial agonism at D2Rs [16,17]. However, the role that D2R partial agonism
plays in the regulation of the Dvl-GSK3 - -catenin signalling pathway by aripiprazole is not
clear. To investigate this issue, we chose a potent D2R partial agonist—bifeprunox [18] to compare
with aripiprazole. Therefore, the present study examined the different effects of one-week oral
administration of aripiprazole on the Akt-GSK3  and Dvl-GSK3 - -catenin signalling pathways in
three schizophrenia-related brain regions in comparison with a D2R antagonist—haloperidol and a
D2R partial agonist—bifeprunox.
2. Results
2.1. Effects of Antipsychotics in the Prefrontal Cortex
Antipsychotic drug administration had significant effects on the expression of total GSK3 
(F3,20 = 3.656, p < 0.05), p-GSK3  (F3,20 = 3.722, p < 0.05) and the ratio of p-GSK3 /GSK3  (F3,20 = 9.207,
p < 0.01) in the PFC, but had no effect on Akt, p-Akt, or the ratio of p-Akt/Akt (Figure 1A,D). Post hoc
tests demonstrated that administration of aripiprazole significantly increased the protein levels of
p-GSK3  by 47.7% ˘ 6.4% (p < 0.05), but reduced total GSK3  expression by 24.9% ˘ 4.7% (p < 0.05)
compared with the control; the ratio of p-GSK3 /GSK3  was also increased by administration of
aripiprazole (p < 0.01) (Figure 1B,D). Furthermore, the protein levels of Dvl-3 and  -catenin in the PFC
were not significantly altered by any antipsychotic drug administration (Figure 1C,D).
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Figure 1. Effects of three antipsychotics in the prefrontal cortex. The effects of aripiprazole (ARI), 
bifeprunox (BIF), haloperidol (HAL), and control (CON) on the activity of protein kinase B (Akt) (A); 
glycogen synthase kinase 3β (GSK3β) (B); and the expression of dishevelled (Dvl)-3 and β-catenin (C) 
were measured in the prefrontal cortex (* p ≤ 0.05, ** p < 0.01 vs. the control). All data were expressed 
as mean ± S.E.M. The representative bands of Western blot are shown in (D). 
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One-way analysis of variance (ANOVA) tests indicated significant effects of antipsychotics on 
the protein levels of total Akt (F3,20 = 9.707, p < 0.01) in the CPu. Post hoc tests showed that the levels of 
total Akt were significantly increased by administration of bifeprunox (+18.7% ± 4.8%, p < 0.05) and 
haloperidol (+37.0% ± 4.0%, p < 0.01) in the CPu (Figure 2A,D); however, they did not affect the levels 
of p-Akt, nor the ratio of p-Akt/Akt. Additionally, the protein levels of Dvl-3 and β-catenin were not 
significantly affected by any antipsychotic drug administration in the CPu (Figure 2B–D). 
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and the expression of Dvl-3 and β-catenin (C) were measured in the caudate putamen (* p ≤ 0.05,  
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Figure 1. Effects of three antipsychotics in the prefrontal cortex. The effects of aripiprazole (ARI),
bifeprunox (BIF), haloperidol (HAL), and control (CON) on the activity of protein kinase B (Akt) (A);
glycogen synthase kinase 3  (GSK3 ) (B); and the expression of dishevelled (Dvl)-3 and  -catenin (C)
were measured in the prefrontal cortex (* p § 0.05, ** p < 0.01 vs. the control). All data were expressed
as mean ˘ S.E.M. The representative bands of Western blot are shown in (D).
2.2. Effects of Antipsychotics in the Caudate Putamen
One-way analysis of variance (ANOVA) tests indicated significant effects of antipsychotics on the
protein levels of total Akt (F3,20 = 9.707, p < 0.01) in the CPu. Post hoc tests showed that the levels of
total Akt were significantly increased by administration of bifeprunox (+18.7% ˘ 4.8%, p < 0.05) and
haloperidol (+37.0% ˘ 4.0%, p < 0.01) in the CPu (Figure 2A,D); however, they did not affect the levels
of p-Akt, nor the ratio of p-Akt/Akt. Additionally, the protein levels of Dvl-3 and  -catenin were not
significantly affected by any antipsychotic drug administration in the CPu (Figure 2B–D).
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2.3. Effects of Antipsychotics in the Nucleus Accumbens
ANOVA tests revealed that antipsychotic drug administration had significant effects on the protein
levels of Akt (F3,20 = 6.792, p < 0.01), GSK3  (F3,20 = 25.381, p < 0.01), p-GSK3  (F3,20 = 11.817, p < 0.01),
the ratio of p-GSK3 /GSK3  (F3,20 = 42.603, p < 0.01), Dvl-3 (F3,20 = 4.121, p < 0.01), and  -catenin
(F3,20 = 10.718, p < 0.01) in the NAc. Post hoc tests indicated that administration of all three chemicals
was shown to be able to reduce the protein levels of total Akt (aripiprazole, ´25.9% ˘ 5.9%, p < 0.01;
bifeprunox, ´16.5% ˘ 5.0%, p < 0.05; haloperidol, ´23.4% ˘ 3.2%, p < 0.01) in the NAc; however, no
antipsychotic drug administration significantly affected the protein levels of p-Akt, nor the ratios of
p-Akt/Akt (Figure 3A,D). Additionally, the expression of total GSK3  was reduced by both aripiprazole
and haloperidol administration (aripiprazole, ´34.5% ˘ 1.2%, p < 0.01; haloperidol, ´15.3% ˘ 7.8%,
p < 0.05). Moreover, both aripiprazole and haloperidol administration was able to elevate the levels
of p-GSK3  (aripiprazole, +64.4% ˘ 11.0%, p < 0.05; haloperidol, +92.4% ˘ 16.7%, p < 0.01) and the
ratios of p-GSK3 /GSK3  (aripiprazole, p < 0.01; haloperidol, p < 0.01) (Figure 3B,D). Furthermore,
it was shown that administration of aripiprazole was able to promote the expression of both Dvl-3
(+64.1% ˘ 11.5%, p < 0.01) and  -catenin (+46.5% ˘ 10.7%, p < 0.01); haloperidol administration
also had a positive effect on the protein levels of both Dvl-3 (+54.8% ˘ 9.4%, p < 0.05) and  -catenin
(+59.9% ˘ 6.6%, p < 0.01) (Figure 3C,D). Lastly, we found that the ratio of p-GSK3 /GSK3  is
positively correlated with the expression of Dvl-3 in the NAc (r = 0.245, p < 0.01) (Figure 4A); the ratio
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Figure 3. Effects of three antipsychotics in the nucleus accumbens. The effects of aripiprazole (ARI), 
bifeprunox (BIF), haloperidol (HAL), and control (CON) on the activity of Akt (A); GSK3β (B);  
and the expression of Dvl-3 and β-catenin (C) were measured in the nucleus accumbens (* p ≤ 0.05,  
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Western blot are shown in (D). 
Figure 3. Effects of three antipsychotics in the nucleus accumbens. The effects of aripiprazole (ARI),
bifeprunox (BIF), haloperidol (HAL), and control (CON) on the activity of Akt (A); GSK3  (B); and the
expression of Dvl-3 and  -catenin (C) were measured in the nucleus accumbens (* p § 0.05, ** p < 0.01
vs. the control). All data were expressed as mean ˘ S.E.M. The representative bands of Western blot
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indicates that inhibition of GSK3  function in the NAc may contribute to the effects of antipsychotics
on the positive symptoms of schizophrenia.
It is worth noting that Akt did not change in parallel with GSK3 , which is not consistent
with previous reports [12,21,25]. This might be explained by following reasons. First, Roh et al. [25]
have reported that the phosphorylation of Akt induced by antipsychotics were much shorter in
duration than those of GSK3 . In the present study, the animals were sacrificed several hours after
the last administration. Therefore, the phosphorylation levels of Akt might have already decreased to
undetectable levels. This might be the major reason that we only observed the altered p-GSK3  levels,
but not p-Akt. Second, there are two phosphorylating sites of Akt—Thr308 and Ser473, both could
be affected by antipsychotic drug administration [4,21,25–27]. The present study has examined the
Thr308 site of Akt only, since phospho-Thr308-Akt was involved in the D2Rs-mediated Akt-GSK3 
signalling [4,27]. However, Akt phosphorylated with either site induces phosphorylation of GSK3 
at Ser9 that was examined in the current study. Thereby, it is possible that the elevated p-GSK3 
levels in this study might be induced by phospho-Ser473-Akt from other signalling pathway(s),
and further investigations are needed to study this issue. Lastly, GSK3  is a multi-targeted regulator.
Antipsychotics might affect GSK3  via alternative pathway(s) rather than the D2Rs-mediated signalling
pathway, such as the Dvl-GSK3 - -catenin signalling pathway.
We have examined the effects of antipsychotics on the Dvl-GSK3 - -catenin signalling pathway.
It was observed that both aripiprazole and haloperidol administration increased the expression
of Dvl-3 and  -catenin in accordance with the enhanced phosphorylation of GSK3  in the NAc,
suggesting that antipsychotics is very likely to affect GSK3  activity via Dvl-GSK3 - -catenin pathway
in this study. However, further studies (e.g., pharmacological or genetic intervention) are required
to confirm this suggestion. In addition, it has been reported that antipsychotics (e.g., aripiprazole,
haloperidol, clozapine, and risperidone) increased the expression of Dvl-3 and/or  -catenin in various
brain regions, including the PFC and striatum [10,12,14]. It is worth noting that the studies by
Alimohamad et al. [12] and Sutton et al. [14] have mixed NAc and CPu together, thus preventing
identification of the sub-region(s) in which the levels of Dvl-3 and  -catenin were increased by
antipsychotic drug administration. This study has separated NAc and CPu, and demonstrated
that antipsychotics affect Dvl-GSK3 - -catenin signalling specifically in the NAc. Taken together,
it suggested that activation of Dvl-GSK3 - -catenin signalling in the NAc is a common route, through
which different classes of antipsychotics exert their effects. Lastly, our results do not show any
alteration in the expression of Dvl-3 and  -catenin in the PFC, which is inconsistent with the findings
of previous studies [10,12,14]. The exact reason remains unclear. This may be because the previous
studies [10,12,14] used intramuscular or subcutaneous injection to deliver the drugs, whereas the
current study used oral treatment with different dosages to mimic the clinical situation. Therefore,
whether the effect of antipsychotics on Dvl-GSK3 - -catenin signalling is treatment method-dependent
requires further validation. Furthermore, one limitation of this study is that the samples have been
investigated by only Western blots method, it is also worthy to further validate these findings using
other methods such as qPCR and immunohistochemistry.
Previously, Min and colleagues [9] have investigated the interaction between the dopaminergic
nervous system and Dvl-GSK3 - -catenin signalling, and found that only D2Rs directly affected
 -catenin distribution in the cell nucleus. The present study used aripiprazole, haloperidol and
bifeprunox, all of which have strong affinity with D2Rs [18,28]. Haloperidol is a potent D2R antagonist,
whereas aripiprazole and bifeprunox are D2R partial agonists. Previous studies have revealed that
the intrinsic activity of aripiprazole at D2Rs is weaker than that of bifeprunox (intrinsic activity at
D2Rs: aripiprazole vs. bifeprunox vs. dopamine = 86.0% vs. 95.1% vs. 100%) [22,29]. Our results
have demonstrated that administration of both aripiprazole and haloperidol, but not bifeprunox,
had significant effects on altering the expression of Dvl-3 and  -catenin in the NAc. Therefore, first,
blockade of D2Rs is (indirectly) linked to the activation of the Dvl-GSK3 - -catenin signalling pathway.
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due to its relatively low intrinsic activity to reduce significantly the activity of endogenous dopamine,
displaying an overall antagonising effect like haloperidol. In contrast, bifeprunox cannot achieve such
effects, probably because of its relatively stronger intrinsic activity at D2Rs. Taken together, our study
suggests that a relatively low intrinsic activity at D2Rs might be essential for a D2R partial agonist to
achieve meaningful effects via affecting the Dvl-GSK3 - -catenin signalling pathway.
4. Materials and Methods
4.1. Animals and Drug Administration
Male Sprague–Dawley rats (aged eight weeks) were obtained from the Animal Resource Centre
(Perth, Australia). After arrival, all rats were housed in individual cages under environmentally
controlled conditions (temperature 22 ˝C, light cycle from 07:00 a.m. to 07:00 p.m.), with ad libitum
access to water and a standard laboratory chow diet. All experimental procedures were approved
by the Animal Ethics Committee (Application #AE11/02, 02/2011), University of Wollongong, and
complied with the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes
(2004). All efforts were made to minimise animal distress and prevent suffering.
Before drug administration commenced, the rats were trained for self-administration of the cookie
dough pellets without drugs. After 1-week training, rats were randomly assigned into one of the
following four groups (n = 6/group): aripiprazole (0.75 mg/kg, t.i.d. (ter in die), Otsuka, Tokyo,
Japan); bifeprunox (0.8 mg/kg, t.i.d., Otava, Kiev, Ukraine); haloperidol (0.1 mg/kg, t.i.d., Sigma,
Castle Hill, Australia); or vehicle for one week. Rats were offered cookies with drugs three times a
day (at 06:00 a.m., 02:00 p.m. and 10:00 p.m.) and observed to ensure complete consumption of each
pellet. The dosages were translated from recommended clinical dosages based on body surface area
according to the FDA guidelines [30,31]. This drug administration method has been well established
in our laboratory [32,33]. Specifically, a 0.75 mg/kg aripiprazole, 0.8 mg/kg bifeprunox and 0.1 mg/kg
haloperidol dosage in rats is equivalent to ~7.5, ~8, and ~1 mg in humans (60 kg body weight),
respectively, all of which are within the used/recommended clinical dosages [34–36]. It is worth
noting that aripiprazole and bifeprunox induced over 90% D2 receptor occupancy in rat brains at these
dosages [18], and haloperidol reached approximately 70% occupancy [37], all of which can display
physiological and behavioural effects in rodents, without inducing EPS side-effects [18,38–40]. After
one-week drug administration, all rats were sacrificed between 10:00 a.m. and 12:00 p.m. to minimise
possible circadian-induced variation of protein expression. All animals were euthanised by using
carbon dioxide. Brains were immediately dissected, frozen in liquid nitrogen and stored at ´80 ˝C
until further use.
4.2. Micro-Dissection of Brain Samples
Following a standard procedure used in our group [8], discrete brain regions were collected using
brain microdissection puncture according to the brain atlas [41]. Briefly, three sections through the
forebrain (Bregma 3.30 to 4.20 mm) were collected for the PFC; and three sections through the striatum
(Bregma 1.00 to 2.20 mm) were collected for the CPu and NAc, respectively. Tissue dissected was kept
at ´80 ˝C.
4.3. Western Blots
The Western blot experiments were performed following standard procedures repeated in
our previous studies [8,33]. Briefly, frozen tissue was homogenised with 9.8 mL NP-40 cell
lysis buffer (Invitrogen, Camarillo, CA, USA) containing 100 µL Protease Inhibitor Cocktail
(Sigma-Aldrich, St. Louis, MO, USA), 100 µL  -Glycerophosphate (Invitrogen) and 33.3 µL
phenylmethylsulfonylfluoride (Sigma-Aldrich). The homogenised samples were centrifuged, and
the supernatants were collected. Protein concentration of each homogenising solution was measured
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10 µg of protein were loaded into 4%–20% Criterion™ TGX™ Precast Gels (Bio-Rad, Hercules, CA,
USA, #5671095) in a Criterion™ Vertical Electrophoresis Cell (Bio-rad, #1656001) at 200 V voltage
for 50 min, and then transferred electrophoretically to a polyvinylidene difluoride membrane in a
Criterion™ Blotter (Bio-rad, #1704071) at 100 V voltage for 60 min. All membranes were blocked by
5% bovine serum albumin (BSA) for 60 min and incubated in primary antibodies (diluted in 1% BSA)
over night. Amersham Hyperfilm ECL (GE Healthcare, Chicago, IL, USA, #28-9068-36) and Luminata
Classico Western HRP substrate (Millipore, Billerica, MA, USA, #WBLUC0500) were used to visualise
the immunoreactive bands. The immunoreactive signals were quantified using Bio-Rad Quantity One
software. The data of each targeted protein were then corrected based on their corresponding actin
levels. Experiments were performed in duplicate to ensure consistency.
The antibodies used in the present study to examine the GSK3 -involved pathways were
anti-Akt (1:2000; Cell Signalling, Danvers, MA, USA, #4691), anti-phosphor-Akt (Thr308) (1:1000;
Cell Signalling, #13038), anti-GSK3  (1:2000; Cell Signalling, #5676), anti-phospho-GSK3  (Ser9)
(1:1000; Cell Signalling, #9322), anti-Dvl-3 (1:1000; Santa Cruz Biotechnology, Dallas, TX, USA,
#SC-8027) and anti- -catenin (1:1000; Santa Cruz Biotechnology, #SC-7963). Mouse anti-actin primary
polyclonal antibody (1:10000; Millipore, #MAB1501) was used to determine the actin levels. The
secondary antibodies were HRP-conjugated anti-rabbit IgG antibody (1:3000; Cell Signalling, #7074)
and HRP-conjugated anti-mouse IgG antibody (1:3000; Cell Signalling, #7076).
4.4. Statistics
All data was analysed using SPSS Statistics V22.0 program (IBM, New York, NY, USA). Data
normality was tested using histograms and a Kolmogorov–Smirnov Z test. For statistical evaluation,
one-way analysis of variance (ANOVA) was performed if the data was normally distributed.
The post hoc Dunnett t test was then conducted to compare each drug treatment group with the
control group. The results of Western blots were normalised by taking the average value of the control
group as 100%. The phosphorylation to total signal was calculated using the data from the same
blot. Pearson’s correlation test was used to analyse the relationships. A p-value of less than 0.05 was
considered as statistically significant.
5. Conclusions
The present study explored the in vivo effects of one-week oral administration of aripiprazole on
the GSK3 -dependent signalling pathways in three brain regions that are associated with schizophrenia
and the actions of antipsychotics, in comparison with haloperidol and bifeprunox. The current study
provides in vivo evidence that inhibition of GSK3  activity in the PFC and NAc might be linked to
the clinical profile of aripiprazole. This study further suggests that, like haloperidol, aripiprazole
can activate Dvl-GSK3 - -catenin signalling in the NAc, which is probably due to the relatively low
intrinsic activity at D2Rs.
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Akt protein kinase B
CPu caudate putamen
D2R dopamine D2 receptor
Dvl dishevelled
EPS extrapyramidal side-effects
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Chronic administration of 
aripiprazole activates GSK3β-
dependent signalling pathways, 
and up-regulates GABAA receptor 
expression and CREB1 activity  
in rats
Bo Pan1,2, Xu-Feng Huang2 & Chao Deng1,2
Aripiprazole is a D2-like receptor (D2R) partial agonist with a favourable clinical profile. Previous 
investigations indicated that acute and short-term administration of aripiprazole had effects on PKA 
activity, GSK3β-dependent pathways, GABAA receptors, NMDA receptor and CREB1 in the brain. 
Since antipsychotics are used chronically in clinics, the present study investigated the long-term 
effects of chronic oral aripiprazole treatment on these cellular signalling pathways, in comparison with 
haloperidol (a D2R antagonist) and bifeprunox (a potent D2R partial agonist). We found that the Akt-
GSK3β pathway was activated by aripiprazole and bifeprunox in the prefrontal cortex; NMDA NR2A 
levels were reduced by aripiprazole and haloperidol. In the nucleus accumbens, all three drugs increased 
Akt-GSK3β signalling; in addition, both aripiprazole and haloperidol, but not bifeprunox, increased 
the expression of Dvl-3, β-catenin and GABAA receptors, NMDA receptor subunits, as well as CREB1 
phosphorylation levels. The results suggest that chronic oral administration of aripiprazole affects 
schizophrenia-related cellular signalling pathways and markers (including Akt-GSK3β signalling,  
Dvl-GSK3β-β-catenin signalling, GABAA receptor, NMDA receptor and CREB1) in a brain-region-
dependent manner; the selective effects of aripiprazole on these signalling pathways might be 
associated with its unique clinical effects.
Aripiprazole is a unique antipsychotic drug with a pharmacological profile different from other available antip-
sychotics, and this difference has been attributed to its partial agonism for the dopamine D2 receptor (D2R). A 
large body of evidence has shown that most antipsychotic drugs (including aripiprazole and haloperidol) have 
a potent affinity at the D2Rs1, regulating the D2R downstream protein kinase B (Akt)-glycogen synthase kinase 
3 beta (GSK3β ) and protein kinase A (PKA) signalling pathways2. In addition, these two signalling pathways 
are also linked to several other pathways or substrates, such as the dishevelled(Dvl)-GSK3β -β -catenin pathway, 
γ -aminobutyric acid (GABA)A receptor and cAMP-responsive element-binding protein 1 (CREB1)3–5.
GSK3β -dependent signalling pathways are involved in the pathophysiology of schizophrenia and the actions 
of antipsychotics4. First, GSK3β is a major downstream regulator of D2-like receptors that is targeted by most 
antipsychotics6. It has been reported that chronic haloperidol treatment phosphorylates GSK3β , and inhibits its 
activity, which is associated with increased phosphorylation levels of Akt in the frontal cortex7. Second, antip-
sychotic administration can also influence the Dvl-GSK3β -β -catenin signalling pathway. Several studies have 
reported that various antipsychotics (including clozapine, haloperidol, risperidone, olanzapine and aripiprazole) 
were able to increase phosphorylation of GSK3β and expression of Dvl and β -catenin in the frontal cortex and 
striatum8–12.
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The G protein-dependent PKA pathway is another downstream signalling pathway of D2-like receptors. PKA 
signalling has been shown to be related to the pathophysiology of schizophrenia by a post-mortem study13. An 
in vivo study has indicated that acute administration of haloperidol and olanzapine increased the expression 
of PKA catalytic subunits in the rat caudate putamen (CPu)14; PKA signalling has also been elevated by acute 
administration of haloperidol in the striatum15; and furthermore, the activity of the PKA pathway and expression 
of PKA regulatory subunits in the striatum were elevated after a 3-week administration of haloperidol in various 
brain regions, but decreased by clozapine administration16. A recent study has shown that 1-week administration 
of aripiprazole increased PKA phosphorylation in the nucleus accumbens (NAc), but reduced it in the CPu, while 
haloperidol decreased it in both the NAc and CPu17.
The GABAA receptor has been reported to be involved in the pathophysiology of schizophrenia18. Increased 
binding density of GABAA receptors have been found in the prefrontal cortex (PFC)19,20, cingulate cortex21, 
superior temporal gyrus22 and hippocampus23 of schizophrenic subjects. Antipsychotic administration has been 
shown to have various effects on GABAA receptors. It has been reported that 1-week treatment with both halo-
peridol and olanzapine increased the binding density of [3H]-Muscimol labelled GABAA receptors24 in the PFC. 
Zink and colleagues25 have found that haloperidol administration for 6 months increased the binding density of 
GABAA receptors in the CPu and core of the NAc, but reduced it in the PFC, anterior cingulate and infralimbic 
cortex; and 6-month clozapine administration reduced the bindings of GABAA receptors in the anterior cingulate 
and infralimbic cortex. Recent data suggested that expression of GABAA receptors in the rat NAc was elevated by 
1-week aripiprazole administration, probably by activation of the PKA pathway17.
CREB1 is also a downstream substrate of the PKA pathway26. Novel variants in the CREB1 gene have been 
identified in schizophrenic subjects, and a relationship between CREB1 and the positive symptoms of schizophre-
nia has been proposed27. Previous in vivo and in vitro studies have shown that haloperidol increased phospho-
rylation levels of CREB128–30. Additionally, amisulpride, clozapine and olanzapine also elevated phosphorylation 
levels of CREB1 in vitro31–33. Furthermore, a 3-week injection of aripiprazole changed the phosphorylation levels 
of CREB1 in the PFC and striatum of rats, probably through NMDA receptors34. A recent short-term study has 
reported that aripiprazole increased the gene and protein expression of CREB1, probably through the PKA path-
way, in the NAc of rats17.
N-methyl-D-aspartate receptors (NMDARs) have been shown to be associated with schizophrenia and can 
be modulated by antipsychotics5. Blockade of NMDARs exacerbates symptoms in schizophrenia individuals35 
or induces abnormal behaviours that resemble the symptoms and cognitive deficits of schizophrenia in healthy 
subjects36,37. Previous studies showed that antipsychotic drug administration had various effects on NMDARs, 
depending on the classes of antipsychotics, treatment methods (e.g. dosages, modes of drug delivery and time 
frames) and brain regions38–41. Therefore, the NMDAR subunits were also examined in the present long-term 
study.
Recent in vivo studies showed that acute and short-term administration of aripiprazole – a potent D2R par-
tial agonist – displayed different effects that cannot be achieved by haloperidol (a typical antipsychotic and a 
potent D2R antagonist) and bifeprunox (a potent D2R partial agonist), providing preliminary in vivo evidence 
that neither D2R partial agonism nor D2R antagonism could be solely explain the pharmacological mechanism 
and unique clinical effects of aripiprazole17,42. It should also be noted that in clinics, antipsychotics require a long 
treatment period to reach maximum therapeutic effect, and thus are often used chronically43. All previous chronic 
studies administered antipsychotics by various methods (e.g. mixing in drinking water, daily injection), rather 
than the oral administration that mimics the clinical situation. The chronic effects of aripiprazole by such oral 
administration are not clear. Therefore, the present study investigated the effects of 10-week oral administration 
of aripiprazole by examining PKA signalling, Akt-GSK3β and Dvl-GSK3β -β -catenin pathways, GABAA receptors 
and CREB1 activity, in comparison with haloperidol and bifeprunox.
Results
The effect of antipsychotics on Akt and GSK3β activity. PFC. It has been shown that the expression 
of total Akt and total GSK3β was significantly affected by 10-week antipsychotic drug administration in the PFC 
(Akt, F3, 20 = 5.201, p = 0.004; GSK3β , F3, 20 = 3.083, p = 0.026); however, the levels of p-Akt and p-GSK3β were not 
significantly affected (p-Akt, F3, 20 = 1.554, p = 0.232; p-GSK3β , F3, 20 = 1.208, p = 0.332). The ratio of p-Akt/Akt 
(F3, 20 = 4.523, p = 0.007) and p-GSK3β /GSK3β (F3, 20 = 4.112, p = 0.010) was also significantly affected by antip-
sychotic drug administration. Post-hoc testing demonstrated that chronic administration of both aripiprazole 
and bifeprunox reduced expression of Akt (aripiprazole, − 14.2%, p = 0.014; bifeprunox, − 13.6%, p = 0.008) in 
the PFC (Fig. 1A,D). Additionally, administration of aripiprazole significantly suppressed GSK3β expression (by 
25.0%; p = 0.043) compared with controls (Fig. 2A,D). The levels of p-Akt and p-GSK3β were not significantly 
affected. In addition, aripiprazole and bifeprunox administration significantly increased the ratio of p-Akt/Akt 
(aripiprazole, p = 0.021; bifeprunox, p = 0.005) (Fig. 1A). The ratio of p-GSK3β /GSK3β was also increased by 
administration of aripiprazole (p = 0.012) and bifeprunox (p = 0.019) (Fig. 2A).
CPu. Chronic antipsychotic drug administration had no significant effects on the levels of Akt, p-Akt (Fig. 1B,D), 
GSK3β and p-GSK3β (Fig. 2B,D) in the CPu compared with controls (all p > 0.05).
NAc. Drug treatment was able to significantly change the levels of p-Akt (F3, 20 = 4.315, p = 0.009), p-GSK3β 
(F3, 20 = 9.798, p < 0.001), as well as the ratio of p-Akt/Akt (F3, 20 = 5.268, p = 0.004) and p-GSK3β /GSK3β (F3, 20 = 7.024, 
p = 0.001) in the NAc. Compared with the control group, both bifeprunox and haloperidol administration 
significantly elevated the levels of p-Akt in the NAc (bifeprunox, + 38.1%, p = 0.010; haloperidol, + 40.8%, 
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Figure 1. Effects of three antipsychotics on Akt activity. The effects of aripiprazole (ARI), bifeprunox (BIF) 
and haloperidol (HAL) on Akt activity were measured in the prefrontal cortex (A), caudate putamen (B) and 
nucleus accumbens (C). The representative bands of Western blot are shown in (D). Akt was quantified at 
60 kDa; p-Akt was quantified at 60 kDa. The data were normalised by taking the average value of the control 
group as 100% and expressed as mean ± S.E.M. (* p ≤ 0.05, * * p < 0.01 vs the control).
Figure 2. Effects of three antipsychotics on GSK3β activity. The effects of aripiprazole (ARI), bifeprunox 
(BIF) and haloperidol (HAL) on GSK3β activity were measured in the prefrontal cortex (A), caudate putamen 
(B) and nucleus accumbens (C). The representative bands of Western blot are shown in (D). GSK3β was 
quantified at 46 kDa; p-GSK3β was quantified at 46 kDa. The data were normalised by taking the average value 




Bo Pan 90 
 
 1 
  2 
www.nature.com/scientificreports/
4Scientific RepoRts | 6:30040 | DOI: 10.1038/srep30040
drugs increased the ratio of p-Akt/Akt (aripiprazole, p = 0.044; bifeprunox, p = 0.007; haloperidol, p = 0.002) 
(Fig. 1C). Furthermore, administration of all three was able to elevate the levels of p-GSK3β (aripiprazole, 
+ 69.3%, p < 0.001; bifeprunox, + 33.2%, p = 0.026; haloperidol, + 38.4%, p = 0.010) (Fig. 2C,D) and significantly 
increased the ratio of p-GSK3β /GSK3β (aripiprazole, p = 0.001; bifeprunox, p = 0.048; haloperidol, p = 0.005) 
(Fig. 2C).
The effect of antipsychotics on Dvl-3 and β-catenin expression. Chronic antipsychotic adminis-
tration had significant effects on the expression of Dvl-3 (F3, 20 = 4.629, p = 0.007) and β -catenin (F3, 20 = 15.704, 
p < 0.001) in the NAc. Post-hoc tests indicated that the protein levels of Dvl-3 were significantly elevated by 
administration of both aripiprazole (+ 40.8%, p = 0.011) and haloperidol (+ 33.7%, p = 0.031) in the NAc; they 
also significantly increased the expression of β -catenin (aripiprazole, + 30.3%, p = 0.008; haloperidol, + 49.6%, 
p < 0.001) (Fig. 3C,D). Additionally, the ratio of p-GSK3β /GSK3β was positively correlated with the expression of 
β -catenin (r = 0.297, p = 0.039) (Fig. 4A). On the other hand, no significant effect was observed in the other two 
brain areas (Fig. 3A,B,D).
The effect of antipsychotics on GABAA receptor expression. GABAA receptors containing β -1 sub-
unit were examined in the present study. The expression of GABAA β -1 receptors in the NAc was significantly 
affected by antipsychotic drug administration (F3, 20 = 4.926, p = 0.005). Both aripiprazole and haloperidol admin-
istration significantly increased GABAA β -1 receptor expression in the NAc, (aripiprazole, + 19.8%, p = 0.008; 
haloperidol, + 22.7%, p = 0.003) (Fig. 3C,D) but not in the PFC and CPu (Fig. 3A,B,D).
The effects of antipsychotics on NMDAR subunits expression. PFC. The expression of NR2A 
was significantly altered by antipsychotic drug administration in the PFC (F3, 20 = 4.976, p = 0.010), but not NR1 
(F3, 20 = 1.067, p = 0.137). Post-hoc tests revealed that NR2A levels were reduced by both aripiprazole (− 19.9%, 
p = 0.020) and haloperidol (− 27.9%, p = 0.002) (Fig. 5A,D).
CPu. The expression of NR1 and NR2A was not affected by drug administration in the CPu (NR1, F3, 20 = 0.082, 
p = 0.969; NR2A, F3, 20 = 0.909, p = 0.454) (Fig. 5B,D).
NAc. Both NR1 and NR2A expression was significantly changed by antipsychotic drug administration (NR1, 
F3, 20 = 4.653, p = 0.013; NR2A, F3, 20 = 6.923, p = 0.002). Post-hoc tests showed that aripiprazole increased the 
expression of both NR1 (+ 36.3%, p = 0.006) and NR2A (+ 41.9%, p = 0.001); haloperidol also elevated NR1 
expression (+ 27.4%, p = 0.033) in the NAc (Fig. 5C,D).
Figure 3. Effects of three antipsychotics on Dvl-3, β-catenin and GABAA (β-1) receptor expression.  
The effects of aripiprazole (ARI), bifeprunox (BIF) and haloperidol (HAL) on the expression of Dvl-3 and  
β -catenin were measured in the prefrontal cortex (A), caudate putamen (B) and nucleus accumbens (C). The 
representative bands of Western blot are shown in (D). Dvl-3 was quantified at 85 kDa; β -catenin was quantified 
at 92 kDa; GABAA (β -1) receptor was quantified at 54 kDa. The data were normalised by taking the average value 
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The effect of antipsychotics on CREB1 activity. The levels of CREB1 and p-CREB1 in the PFC 
and CPu were not altered by any of the three antipsychotic drug administration (Fig. 6A,B,D). In the NAc, 
antipsychotic drug administration had a significant effect on CREB1 (F3, 20 = 2.502, p = 0.045), p-CREB1 
(F3, 20 = 10.698, p < 0.001), as well as the ratio of p-CREB1/CREB1 (F3, 20 = 5.972, p = 0.002). Post-hoc tests showed 
that the expression of CREB1 was significantly elevated by administration of aripiprazole (+ 30.5%; p = 0.020). 
Additionally, the levels of p-CREB1 were significantly promoted by aripiprazole (+ 90.0%, p < 0.001) and halop-
eridol (+ 68.8%, p = 0.002) in the NAc (Fig. 6C,D); they also elevated the ratio of p-CREB1/CREB1 (aripiprazole, 
p = 0.019; haloperidol, p = 0.004) (Fig. 6C). Furthermore, the ratio of p-GSK3β /GSK3β was positively correlated 
with the ratio of p-CREB1/CREB1 (r = 0.572, p = 0.012) in the NAc (Fig. 4B).
The effect of antipsychotics on PKA activity. The levels of PKA-Cα and p-PKA-C were not changed in 
any brain regions after chronic antipsychotic administration in the present study (data not shown).
Figure 4. Correlations between the ratio of p-GSK3β/GSK3β and the ratio of the expression of β-catenin, 
and the ratio of p-CREB1/CREB1 in the NAc. The ratio of p-GSK3β /GSK3β was positively correlated with the 
expression of β -catenin (A), as well as the ratio of p-CREB1/CREB1 (B).
Figure 5. Effects of three antipsychotics on NMRA receptor subunits expression. The effects of aripiprazole 
(ARI), bifeprunox (BIF) and haloperidol (HAL) on the expression of NMDA receptor subunits NR1 and 
NR2A were measured in the prefrontal cortex (A), caudate putamen (B) and nucleus accumbens (C). The 
representative bands of Western blot are shown in (D). NR1 was quantified at 105 kDa; NR2A was quantified at 
165 kDa. The data were normalised by taking the average value of the control group as 100% and expressed as 
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Discussion
The present study investigated the chronic effects of aripiprazole on Akt-GSK3β and Dvl-GSK3β -β -catenin sig-
nalling, PKA activity, GABAA (containing β -1) receptor expression, NMDAR subunits expression and CREB1 
activity in three brain regions, compared with haloperidol and bifeprunox. This is the first study to examine the 
chronic in vivo effects of aripiprazole on these cellular signalling pathways. The results have shown that all three 
antipsychotics had different effects on these signalling pathways, depending on the antipsychotic and the brain 
region.
Elevated Akt-GSK3β signalling in the pathophysiology of schizophrenia has been reported in a number of 
studies4,7,44–47. Various antipsychotics have shown increasing effects on the Akt-GSK3β signalling pathway in 
previous studies7–9,48,49. Previous acute and 1-week studies have also demonstrated that both aripiprazole and 
haloperidol increase the levels of p-GSK3β , but not p-Akt12,42. In the current study, chronic administration of all 
three drugs was able to increase the ratio of p-Akt/Akt and p-GSK3β /GSK3β in various brain regions, indicat-
ing reduced GSK3β activity in these brain areas; this is generally consistent with the findings of previous acute 
and short-term studies. It is worthy to note that aripiprazole is not only a D2R partial agonist, but also a biased 
antagonist at the β -arrestin250. It has been shown that inhibition of D2R mediated β -arrestin2-GSK3β signalling 
pathway is a common property that contributes to the therapeutic effects of various antipsychotics, including 
aripiprazole50–52, which has been confirmed in this chronic study. It should also be noted that antipsychotics 
affect Akt-GSK3β signalling in a time-dependent manner. Roh et al.53 found that the duration of p-Akt signalling 
induced by antipsychotics (about 1 hour) was much shorter than that of p-GSK3β . The time interval between the 
last administration and sacrifice in the previous12,42 and the present studies was longer than 1 hour. The levels of 
p-Akt were undetectable in the acute and short-term studies12,42, but were observed in this chronic study, which 
suggests that chronic administration of antipsychotic drugs might be able to have prolonged effects on Akt activ-
ity and thereby on Akt-GSK3β signalling.
Although aripiprazole, bifeprunox and haloperidol were able to influence GSK3β activity in the present study, 
their effects on GSK3β were not identical in each brain region. In the PFC, administration of aripiprazole and 
bifeprunox, but not haloperidol, was able to suppress the activity of GSK3β via the Akt-GSK3β signalling pathway. 
Aripiprazole and bifeprunox also decreased total protein levels of both Akt and GSK3β in response to the chronic 
treatment of these two drugs. It has been suggested that inhibition of GSK3β contributes to the therapeutic effects 
of antipsychotics48 and the functional impairment in the PFC is related to the negative symptoms and cognitive 
deficits of schizophrenia54. Our results suggested that the therapeutic effects of aripiprazole on the negative symp-
toms and cognitive deficits of schizophrenia might be attributed to its inhibiting effects on GSK3β activity in the 
PFC. Furthermore, bifeprunox was able to improve the negative symptoms of schizophrenia in clinical trials55 
and it inhibited the activity of GSK3β in the present study, which further confirms that suppression of GSK3β 
activity is very likely to be associated with the effects of antipsychotics on the negative and cognitive symptoms 
Figure 6. Effects of three antipsychotics on CREB1 activity. The effects of aripiprazole (ARI), bifeprunox 
(BIF) and haloperidol (HAL) on CREB1 activity were measured in the prefrontal cortex (A), caudate putamen 
(B) and nucleus accumbens (C). The representative bands of Western blot are shown in (D). CREB1 was 
quantified at 40 kDa; p-CREB1 was quantified at 37 kDa. The data were normalised by taking the average value 
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of schizophrenia. In contrast, haloperidol did not display any significant effects on GSK3β in the PFC in the 
present study and a previous acute study42, which may explain why haloperidol does not have therapeutic effects 
on the negative symptoms and cognitive deficits of schizophrenia. It should be noted that the present study did 
not found any changes of β -catenin, CREB1 and GABAA receptor in the PFC. Therefore, whether antipsychotics 
control the negative symptoms and cognitive deficits of schizophrenia via the enhancement of Akt-GSK3β signal-
ling requires further validations. In the NAc, administration of all three drugs increased the phosphorylation of 
both Akt and GSK3β in the present study. Since abnormal function of the NAc is linked to the positive symptoms 
of schizophrenia56, our results indicated that the suppression of GSK3β functions via the Akt-GSK3β signalling 
pathway in the NAc is very likely to be involved in the therapeutic effects of antipsychotics (probably on the 
positive symptoms of schizophrenia) (Fig. 7A). In the CPu, chronic treatment with these antipsychotics had very 
limited effects on the Akt-GSK3β signalling pathway, which suggests that GSK3β activity in the CPu may not be 
involved in the long-term clinical effects of antipsychotics. Yager et al.57 have reviewed that the NAc and CPu 
are heterogeneous structures with different neural inputs and outputs connected with various brain regions. For 
example, the NAc receives dopaminergic inputs from the ventral tegmental area, while sending outputs to limbic 
areas and the PFC; the CPu receives dopaminergic inputs from the substantia nigra pars, while sending projec-
tions to neocortical areas57. Therefore, chronic antipsychotic treatment might have different in the NAc and CPu. 
However, the brain-regional differences in the effects of antipsychotics require further clarification.
Previously, various classes of antipsychotics (e.g. aripiprazole, haloperidol, clozapine and risperidone) have 
been found to be able to increase the expression of Dvl-3 and/or β -catenin in various brain regions of animals, 
including the frontal cortex and striatum, indicating enhanced activity of β -catenin in these brain areas8–11. The 
current data has demonstrated that Dvl-3 and β -catenin expression was significantly increased by administration 
of both aripiprazole and haloperidol in the NAc only. These results are partly consistent with those of previous 
studies. Since dysfunction of the NAc is associated with the positive symptoms of schizophrenia and the main 
target of antipsychotics56 as mentioned above, the present study suggests that regulation of β -catenin via GSK3β 
might be a common mechanism by which antipsychotics exert their effects, even if they have different pharmaco-
logical profiles (Fig. 7A). It is further suggested that the increased expression of β -catenin in the NAc is very likely 
to be a route through which antipsychotics exert their therapeutic effects, especially on the positive symptoms of 
schizophrenia.
It has been reported that chronic haloperidol administration increased the binding of GABAA receptors in the 
NAc; and both haloperidol and clozapine administration also increased GABAA receptor binding in the limbic 
cortex25. A recent short-term study has demonstrated that both aripiprazole and haloperidol increased GABAA 
(containing β -1) receptor expression in the NAc (although the increasing effect of haloperidol did not reach 
significance)17, which is validated by the present study. In this study, we found that chronic administration of 
Figure 7. A proposed schematic diagram illustrating the chronic effects of aripiprazole and haloperidol on 
cellular signalling in the nucleus accumbens. D2 receptor antagonists (e.g. haloperidol) and D2 receptor partial 
agonists (e.g. aripiprazole) bind with the dopamine D2-like receptor, resulting in the phosphorylation of Akt 
and the subsequent phosphorylation of GSK3β probably via biasedly antagonising D2R-mediated β -arrestin2, 
together with the activation of the Dvl-GSK3β -β -catenin pathway (A), which might contribute to the therapeutic 
effect of antipsychotics. On the other hand, antagonism of the D2-like receptors by aripiprazole and haloperidol 
leads to increased expression of GABAA (β -1) receptors probably via the activation of PKA activity (indicated as 
a dashed arrow) (B), and enhanced CREB1 activity via the activation of GSK3β activity and PKA activity  
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aripiprazole and haloperidol were able to significantly increase GABAA (containing β -1) receptor expression in 
the NAc, but no effects were shown in the other two brain regions. Since dysfunction of the NAc is related to the 
positive symptoms of schizophrenia56 as mentioned above, our findings together with other studies, suggest that 
increased GABAA receptor expression and probably enhanced GABAA signalling transmission in the NAc is very 
likely to be involved in the therapeutic effects of antipsychotics (possibly on the positive symptoms of schizophre-
nia) (Fig. 7B). It is worth noting that the GABAA receptor is regulated by D2-like receptor downstream PKA sig-
nalling58,59. A 1-week study has revealed that PKA phosphorylation levels in the NAc, paralleling the expression 
of GABAA receptors, was increased by aripiprazole and haloperidol17. In this chronic study, the effects of aripipra-
zole and haloperidol in increasing GABAA receptor expression persisted, whereas the changes in PKA activity 
were undetectable. The reason is unknown. It is possible that the up-regulated expression of GABAA receptors by 
short-term antipsychotic drug administration (through PKA) is an adaptive and prolonged change; even if there 
was no further alteration in PKA activity after chronic administration (probably due to adaptive changes in D2Rs), 
the increased GABAA receptor expression could be maintained.
A variety of studies has indicated dysfunction of NMDARs in schizophrenia5. In the current study, both arip-
iprazole and haloperidol administration was able to increase the expression of NMDAR subunits in the NAc, but 
reduce it in the PFC. Specifically, aripiprazole increased the expression of both NR1 and NR2A in the NAc, while 
haloperidol increased NR1 expression; in the PFC, both aripiprazole and haloperidol decreased NR2A levels. 
Previously, Segnitz et al.41 have reported that NR2A mRNA levels were decreased in the PFC by aripiprazole 
treatment for 4 months, but not changed in the CPu; Schmitt et al.40 have also found reduced NR2A mRNA in the 
PFC induced by both haloperidol and clozapine treatment. Furthermore, it was found that 4-week administration 
with haloperidol and D2-like receptor antagonist – raclopride increased the levels of both protein and mRNA 
of NR1 in the striatum39. Additionally, [3H]-MK-801 binding in the NAc was increased by haloperidol40. These 
previous findings are consistent with those of this study that both typical and atypical antipsychotics can increase 
NMDARs expression in the striatum (particularly in the NAc, but not in CPu), and reduce NR2A expression in 
the PFC. It is worth noting that antipsychotics have very low affinity with NMDARs. Therefore, it is necessary to 
further reveal through which pathway(s) antipsychotics regulate NMDARs.
Previously, haloperidol was able to increase phosphorylation levels of CREB1 in the striatum and hippocam-
pal neuron culture28–30. In addition, amisulpride, clozapine and olanzapine were also able to induce CREB1 phos-
phorylation in in vitro studies31–33. A 1-week in vivo study has shown that a 1-week administration of aripiprazole 
increased the expression of CREB1 in the NAc17. In the present study, chronic administration of aripiprazole 
increased CREB1 expression in the NAc; and both aripiprazole and haloperidol enhanced CREB1 activity via 
increasing the ratio of p-CREB1/CREB1. This confirmed that CREB1 is involved in the actions of antipsychotics. 
Moreover, extensive communication occurs between CREB1 and PKA, and the Akt-GSK3β pathway60. In the 
present study, we did not observe any change in PKA activity, nor in the correlation between PKA and CREB1 
activity in the NAc (indicated as a dashed arrow in Fig. 7C). However, GSK3β activity is positively correlated with 
CREB1 activity. A previous study has indicated that CREB1 activity was increased by inhibition of GSK3β in cul-
tured rat cerebral cortical neurons33. Amisulpride also induced the phosphorylation of CREB1 via the Akt-GSK3β 
pathway in SH-SY5Y cells32. Since patients with novel variants in the CREB1 gene experienced the positive symp-
toms of schizophrenia27, our data suggests that activation of CREB1 via the Akt-GSK3β pathway in the NAc is 
very likely to be associated with the therapeutic effects of aripiprazole and haloperidol on the positive symptoms 
of schizophrenia (Fig. 7C). It is worth noting that Mavrikaki et al.34 suggested that phosphorylation of CREB1 was 
increased by 3-week injection of aripiprazole in the PFC and striatum of rats, probably through NMDA recep-
tors. The regulation of CREB1 via NMDARs has also been confirmed by other studies61,62. The present study has 
shown both aripiprazole and haloperidol were able to increase CREB1 phosphorylation and NMDAR expression 
in the NAc, simultaneously. Whether the increased expression of NMDARs (partly) contributes to the enhanced 
phosphorylation of CREB1 in the NAc requires further validations. Lastly, phosphorylation of histone H3S10, an 
epigenetic modification, has been reported to be significantly increased in schizophrenia patients63. Since histone 
H3 phosphorylation could be regulated by G protein-coupled receptor and NMDAR signalling64, it is important 
to further investigate how the modulations of antipsychotics on these signalling pathways contribute to their 
therapeutic effects.
In summary, the present study has demonstrated that chronic administration of aripiprazole had dif-
ferent effects on the Akt-GSK3β , Dvl-GSK3β -β -catenin, GABAA receptor and CREB1 activity in a brain 
region-dependent manner. Compared to the effects of haloperidol only in the NAc and bifeprunox mainly in 
the PFC, aripiprazole affected these cellular signalling pathways in both the PFC and NAc, which may explain its 
unique clinical effects. It is also worth noting that the present and previous studies mentioned above examined 
the effects of antipsychotic drugs in healthy animals. It is necessary to investigate the effects of antipsychotics in 
the animal models for schizophrenia and other mental disorders in future studies.
Methods
Animals and drug administration. Male Sprague-Dawley rats (aged 8 weeks) were obtained from the 
Animal Resource Centre (Perth, Australia). After arrival, all rats were housed in individual cages under envi-
ronmentally controlled conditions (temperature 22 °C, light cycle from 07:00AM to 07:00PM), with ad libitum 
access to water and standard laboratory chow diet. All experimental procedures were approved by the Animal 
Ethics Committee (Application #: AE11/02), University of Wollongong, and complied with the Australian Code 
of Practice for the Care and Use of Animals for Scientific Purposes (2004). All efforts were made to minimise 
animal distress and prevent suffering.
Before drug administration commenced, the rats were trained for self-administration of the sweet cookie 
dough pellets for a week. Then the rats were randomly assigned into one of the following drug treatment groups 
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(0.1 mg/kg; Sigma, Australia), or vehicle. Drug powder mixed with the cookie dough pellets was delivered orally 
3 times per day at 07:00AM, 03:00PM and 11:00PM for 10 weeks. This drug administration method aims to 
mirror the human scenario of oral administration and has been well-established in our laboratory17,65,66. These 
dosages were transferred from the recommended dosages in humans based on body surface area, according to 
the FDA guidelines for clinical trials67,68. A 0.75 mg/kg aripiprazole, 0.8 mg/kg bifeprunox and 0.1 mg/kg halo-
peridol dosage in rats is equivalent to ~7.5 mg, ~8 mg and ~1 mg in humans (60 kg body weight), respectively, 
all of which are within the recommended clinical dosages55,69,70. Moreover, the dosages used in this study have 
been shown to be physiologically and behaviourally effective in rodents, without inducing EPS side-effects71–74. 
After 10-week administration, all animals were euthanised in a CO2-filled chamber. Brains were immediately 
removed and frozen in liquid nitrogen. All animals were sacrificed between 09:00AM and 11:00AM to minimise 
circadian-induced variation of protein expression.
Brain dissection. The discrete brain regions were collected using a brain microdissection puncture tech-
nique, which has been well-established17,42. Specifically, based on the brain atlas75, three sections through the fore-
brain (Bregma 3.30 to 4.20 mm) were dissected for the PFC; and three sections through the striatum (Bregma 1.00 
to 2.20 mm) were dissected for the NAc and CPu, respectively. Dissected tissue was kept at − 80 °C for future use.
Western blots. Frozen brain samples were homogenised in homogenising buffer (9.8 ml NP-40 cell lysis 
buffer (Invitrogen, #FNN0021) mixed with 100 µ l Protease Inhibitor Cocktail (Sigma-Aldrich, #P8340), 100 µ l 
β -Glycerophosphate (Sigma-Aldrich, #G9422) and 33.3 µ l phenylmethylsulfonyl fluoride (Sigma-Aldrich, 
#P7626)). Protein concentration of each sample was measured by the DC Protein Assay (Bio-Rad, #500-0111). 
Each sample containing 10 µ g of protein was denatured at 95 °C, and loaded into 4–20% CriterionTM TGXTM 
Precast Gels (Bio-rad, #5671095). The gels were run vertically in CriterionTM Vertical Electrophoresis Cell 
(Bio-rad, #1656001) until the proteins separated, followed by the electrophoretical transfer of the proteins 
to a polyvinylidene difluoride membrane in CriterionTM Blotter (Bio-rad, #1704071). All membranes were 
then blocked by 5% skim milk powder and incubated in primary antibodies. Amersham Hyperfilm ECL (GE 
Healthcare, #28-9068-36) and Luminata Classico Western HRP substrate (Millipore, #WBLUC0500) were used 
to visualise the immunoreactive bands. All Western blot experiments were performed in duplicate to ensure 
consistency.
The antibodies used in the present study to examine PKA activity were anti-PKA-Cα (1:1000; Santa Cruz, 
#SC-903) and anti-phosphor-PKA-C (Thr197) (1:1000; Cell Signalling, #5661). The antibodies used to exam-
ine the GSK3β -involved pathways were anti-Akt (1:2000; Cell Signalling, #4691), anti-phosphor-Akt (Thr308) 
(1:1000; Cell Signalling, #13038), anti-GSK3β (1:2000; Cell Signalling, #5676), anti-phospho-GSK3β (Ser9) 
(1:1000; Cell Signalling, #9322), anti-Dvl-3 (1:1000; Santa Cruz Biotechnology, #SC-8027), anti-β -catenin 
(1:1000; Santa Cruz Biotechnology, #SC-7963). The antibodies used to detect subunits of GABAA receptors were: 
anti-GABAA β -1 (1:1000; Abcam, #ab154822), anti-GABAA β -2 (1:1000; Abcam, #ab156000), and anti-GABAA 
β -3 (1:1000; Abcam, #ab98968). The antibodies used to examine NMDAR were anti-NMDAR1 (1:2000, Abcam, 
#ab109182) and anti-NMDAR2A (1:500, Abcam, #ab124913). In addition, anti-CREB1 (1:2000, Abcam, 
#ab32515) and anti-phospho-CREB11 (1:2000, Abcam, #ab32096) were used to measure the activity of CREB1. 
Mouse anti-actin primary polyclonal antibody (1:10000; Millipore, #MAB1501) was used to determine the actin 
levels. The secondary antibodies were HRP-conjugated anti-rabbit IgG antibody (1:3000; Cell Signalling, #7074) 
and HRP-conjugated anti-mouse IgG antibody (1:3000; Cell Signalling, #7076). Examples of full pictures of the 
blots for each antibody are shown in the Supplementary file.
Statistics. All data were analysed using SPSS Statistics V22.0 program. The immunoreactive signals 
were quantified using Bio-Rad Quantity One software. The data of each targeted protein were then cor-
rected based on their corresponding actin levels. Data normal distribution was tested using histograms and a 
Kolmogorov-Smirnov Z test. For statistical evaluation, one-way analysis of variance (ANOVA) was performed 
if the data was normally distributed. The post-hoc Dunnett t test was used to compare each drug treatment 
group with the control group. The results were normalised by taking the value of the control group as 100%. 
Pearson’s correlation test was used to analyse the relationships among the measurements. Statistical significance 
was accepted when p ≤ 0.05.
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 1 
CHAPTER 7   GENERAL DISCUSSION 2 
7.1 Overall discussion 3 
As discussed in earlier chapters, aripiprazole possesses favourable clinical effects and 4 
reduced side-effects (e.g. EPS), which have been attributed to its partial agonism for 5 
D2Rs (Di Sciascio and Riva, 2015). However, since all other D2R partial agonists either 6 
fail to achieve meaningful therapeutic effects and/or induce severe side-effects, the 7 
contribution of the D2R partial agonism to the unique effects of aripiprazole has been 8 
questioned. Therefore, it is important to understand the cellular mechanism of 9 
aripiprazole to validate the role of the D2R partial agonism in the clinical action of 10 
aripiprazole. This thesis investigated the effects of aripiprazole on the D2R-mediated 11 
PKA and Akt-GSK3β signalling pathways, as well as potential regulators of these two 12 
pathways, in the key brain regions related to the pathophysiology of schizophrenia and 13 
actions of antipsychotics, in comparison with bifeprunox (a D2R partial agonist) and 14 
haloperidol (a D2R antagonist). The current thesis is also the first study to investigate 15 
the effects of aripiprazole on these cellular signalling pathways by employing oral 16 
administration to mimic clinical treatment situation of aripiprazole. The following key 17 
outcomes have been achieved. 18 
 19 
7.1.1 Effects of aripiprazole on various cellular pathways and regulators 20 
The present studies have demonstrated that aripiprazole is able to modulate both the 21 
PKA and Akt-GSK3β signalling pathways, as well as the Dvl-GSK3β-β-catenin 22 
pathways, the GABAA receptor and CREB1. Acute administration of aripiprazole 23 




Bo Pan 100 
 
phosphorylation (Chapter 3). As reported in Chapters 4 and 5, 1-week administration of 1 
aripiprazole significantly increased the phosphorylation of PKA in the NAc, but, 2 
interestingly, reduced it in the CPu; the phosphorylation levels of GSK3β were elevated 3 
by aripiprazole administration in both the PFC and NAc. It is worth noting that the 4 
phosphorylation of Akt did not change in the acute and short-term study. Furthermore, 5 
1-week administration of aripiprazole increased the expression of Dvl-3, β-catenin, 6 
GABAA (containing β-1) receptors, as well as total CREB, in the NAc. In the 10-week 7 
study (Chapter 6), the increased phosphorylation of GSK3β in the PFC and NAc 8 
persisted after chronic administration of aripiprazole. Additionally, long-term 9 
aripiprazole administration also elevated the expression of Dvl-3, β-catenin and GABAA 10 
receptors in the NAc. 11 
 12 
7.1.1.1 Aripiprazole activates GSK3β-dependent signalling pathways 13 
This thesis has shown that aripiprazole increased the phosphorylation of GSK3β in all 14 
acute, short- and long-term studies, but the phosphorylation of Akt was observed only in 15 
the chronic study (Chapter 6). Previous evidence has revealed that various 16 
antipsychotics with antagonism for the D2R increase the phosphorylation of Akt with a 17 
concomitant increase in phosphorylated GSK3β (Beaulieu et al., 2004; Emamian et al., 18 
2004) (aripiprazole was not examined). In addition, in vitro studies have reported that 19 
aripiprazole, unlike other antipsychotics, did not facilitate the D2L receptor-mediated β-20 
arrestin2-Akt-GSK3β signalling pathway (Klewe et al., 2008; Masri et al., 2008). Our 21 
study (Chapter 6) is the first study to provide in vivo evidence that aripiprazole is able to 22 
activate Akt-GSK3β signalling in the PFC and NAc. This finding suggests that 23 
activation of GSK3β signalling is associated with the actions of aripiprazole; and 24 
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agonist. It is worth noting that only the 10-week study (Chapter 6) revealed increased 1 
Akt phosphorylation, which suggests that oral administration of aripiprazole, on current 2 
dosage, might require long-term use to stabilise its increase in Akt-GSK3β signalling. 3 
 4 
Previous studies have indicated that antipsychotics (including haloperidol and clozapine) 5 
have various effects on the Dvl-GSK3β-β-catenin signalling pathway in vitro and in 6 
vivo (Alimohamad et al., 2005a; Alimohamad et al., 2005b; Sutton et al., 2007; Sutton 7 
and Rushlow, 2011). In addition, it has been reported that systematic administration of 8 
aripiprazole for 3 weeks was able to elevate the phosphorylation levels of GSK3β and 9 
the expression of β-catenin in the PFC and hippocampus (Park et al., 2011a; Seo et al., 10 
2015). The present studies (Chapter 5 and 6) have demonstrated that aripiprazole has 11 
similar effects on the Dvl-GSK3β-β-catenin signalling pathway in the NAc, which 12 
suggests that regulation of the Dvl-GSK3β-β-catenin signalling pathway is very likely 13 
to be involved in the clinical effects of antipsychotics. However, a brain regional 14 
difference emerged between the present and previous studies (Park et al., 2011a; Seo et 15 
al., 2015). The exact reason for this brain regional difference is not clear. It might be 16 
because of the different treatment methods and dosages. For example, animals in Park’s 17 
study (2011a) and Seo’s study (2015) received daily injections of aripiprazole (1.5 18 
mg/kg/day), while our studies employed oral administration (0.75 mg/kg/day). This 19 
issue needs to be further investigated. 20 
 21 
7.1.1.2 The effects of aripiprazole on PKA signalling 22 
This thesis has shown that aripiprazole had inconsistent effects on PKA signalling. In 23 
the acute study (Chapter 3), aripiprazole affected the expression of PKA, but not its 24 
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effects in altering the PKA phosphorylation in both NAc and CPu, whereas these effects 1 
were not observed in the chronic study (Chapter 6). These findings suggest that PKA 2 
signalling might be involved in the short-term actions of aripiprazole; however, PKA 3 
signalling, unlike Akt-GSK3β pathway, might not be associated with the long-term 4 
clinical effects of aripiprazole. 5 
 6 
7.1.1.3 Aripiprazole up-regulates GABAA receptors 7 
Although none of the antipsychotics used in the present studies directly bind with 8 
GABAA receptors, both short- and long-term administration of aripiprazole (Chapters 4 9 
and 6) increased the expression of GABAA (containing β-1) receptors in the NAc. 10 
Previously, only one image study showed that GABAA receptor binding potential was 11 
reduced by aripiprazole administration in the left frontopolar cortex and right premotor 12 
cortex (Lee et al., 2013). Other antipsychotics in previous studies had discrepant effects 13 
on the binding density of GABAA receptors (McLeod et al., 2008; Skilbeck et al., 2007; 14 
Zink et al., 2004). Our studies are the first studies to examine the effects of aripiprazole 15 
on the protein levels of GABAA receptors in the brain. Both the current short- and long-16 
term studies have shown similar effects of aripiprazole on GABAA receptors, which 17 
confirms that up-regulation of GABAA receptors is very like to be involved in the 18 
actions of aripiprazole. 19 
 20 
It should be noted that aripiprazole has very low affinity for GABAA receptors. 21 
Therefore, aripiprazole regulates GABAA receptors via indirect pathway(s). One 22 
possible pathway is the D2R downstream PKA signalling pathway (Connelly et al., 23 
2013; Poisbeau et al., 1999). Our short-term study (Chapter 4) has revealed that the 24 
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the increased phosphorylation of PKA. It is very interesting that in the chronic study 1 
(Chapter 6), the increasing effects of aripiprazole on GABAA receptors persisted, but 2 
PKA did not change. The exact reason is unknown. It might be because after long-term 3 
administration, the protein levels of GABAA receptors are stabilised, even without the 4 
alteration in PKA signalling. It is also possible that aripiprazole might regulate GABAA 5 
receptors in alternative manners. For example, aripiprazole can regulate the expression 6 
of glutamic acid decarboxylase 67 and GABA transporters (Peselmann et al., 2013), 7 
which might change the intercellular levels of GABA and subsequently affect GABA 8 
receptors.  9 
 10 
7.1.1.4 Aripiprazole activates CREB1 11 
The present data have demonstrated that aripiprazole affected CREB1 (Chapter 4 and 6). 12 
Previous studies have reported that various antipsychotics (including haloperidol, 13 
amisulpride, clozapine and olanzapine) were able to increase phosphorylation levels of 14 
CREB1 in vitro and in vivo (Jeon et al., 2015; Konradi and Heckers, 1995; Liang and 15 
Chuang, 2006; Park et al., 2011b; Pozzi et al., 2003; Yang et al., 2004). Therefore, the 16 
present study (Chapter 6) has confirmed the role of CREB1 in the actions of 17 
antipsychotics. 18 
 19 
It should be noted that CREB1 can be regulated by both Akt-GSK3β and PKA 20 
signalling (Lonze and Ginty, 2002). Previous in vitro studies have indicated that 21 
CREB1 activity was increased by inhibition of GSK3β via the Akt-GSK3β pathway in 22 
cultured rat cerebral cortical neurons and SH-SY5Y cells (Liang and Chuang, 2006; 23 
Park et al., 2011b). As discussed in Chapters 4, 5 and 6, aripiprazole affects both 24 
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correlated with the phosphorylation of CREB1. Therefore, our studies support the 1 
proposition that antipsychotics might affect CREB1 via the Akt-GSK3β signalling 2 
pathway. On the other hand, the effects of antipsychotics on the PKA activity were 3 
observed only in the short-term study (Chapter 4). Further studies are necessary to 4 
validate whether aripiprazole affects CREB1 via PKA signalling (see Section 7.2 for 5 
recommended studies). 6 
 7 
7.1.2 The time-dependent effects of aripiprazole 8 
The short- and long-term studies have also shown that aripiprazole exerts its effects in a 9 
time-dependent manner. In the short-term study, aripiprazole and haloperidol increased 10 
phosphorylation of PKA (Chapter 4), but not Akt (Chapter 5), whereas, in the long-term 11 
study, aripiprazole induced Akt activation, but not PKA (Chapter 6). These findings 12 
suggest that PKA signalling is very likely to be involved in the short-term effects of 13 
aripiprazole, while Akt signalling is associated with the prolonged effects of 14 
aripiprazole. It should be noted that the up-regulation of Dvl-β-catenin, GABAA 15 
receptors and CREB1 induced by aripiprazole appeared time-independent in both the 16 
short- and long-term studies. The exact reason is not clear. It is possible that 17 
antipsychotic drug administration not only induced the alterations in these pathways and 18 
regulators, it also caused adaptive changes in the synapses; therefore, even if 19 
aripiprazole changes its effects on Akt and PKA activity after chronic administration 20 
(probably due to adaptive changes in D2Rs), the prolonged alterations in these pathways 21 
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7.1.3 A relatively low intrinsic activity for D2Rs is essential for aripiprazole 1 
The present studies have compared aripiprazole with bifeprunox and haloperidol. It has 2 
been demonstrated that aripiprazole had generally similar effects on Akt-GSK3β 3 
signalling, Dvl-GSK3β-β-catenin signalling, GABAA receptors expression and CREB1 4 
activity as haloperidol in the NAc in the short- and long-term studies. These findings 5 
suggest that aripiprazole is very likely to display similar antagonistic effects to inhibit 6 
D2 receptor-downstream signalling in the NAc as haloperidol, even though it is a D2R 7 
partial agonist. As discussed in the Section 2.3.4.1, among these three drugs, bifeprunox 8 
has the highest intrinsic activity for D2Rs, higher than that of aripiprazole and 9 
haloperidol (intrinsic activity for long-form D2Rs in vitro: dopamine vs. bifeprunox vs. 10 
aripiprazole vs. haloperidol = 100% vs. 95.1% vs. 86.0% vs. antagonist) (Tadori et al., 11 
2007; Tadori et al., 2005) (Table 2-2). Since with the exception of aripiprazole, no other 12 
D2R partial agonist has been successful in the treatment of schizophrenia, the present 13 
studies suggest that a relatively low intrinsic activity to achieve antagonistic effects on 14 
D2Rs might be essential for a D2R partial agonist to exert meaningful therapeutic effects 15 
in schizophrenia.  16 
 17 
7.1.4 Proposed cellular mechanisms of aripiprazole in the nucleus accumbens 18 
The present studies have indicated that aripiprazole has consistent effects on the PKA 19 
and Akt-GSK3β signalling pathways, as well as the Dvl-GSK3β-β-catenin signalling 20 
pathway, GABAA receptors and CREB1 in the NAc. As discussed before, these cellular 21 
effects of aripiprazole might be attributed to its relatively low intrinsic activity for D2Rs. 22 
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shown in Fig. 7-1. Due to its relatively low intrinsic activity, aripiprazole is able to 1 
antagonise D2Rs (Fig. 7-1A), resulting in increased phosphorylation levels of Akt and  2 
 3 
Fig. 7-1 A schematic diagram of the proposed cellular mechanisms of aripiprazole in 4 
the nucleus accumbens. 5 
(A) aripiprazole antagonises D2Rs due to its relatively low intrinsic activity for D2Rs; 6 
(B) aripiprazole increases the phosphorylation of Akt and GSK3β (inhibiting GSK3β 7 
function), and the expression of Dvl-3 and β-catenin (elevating β-catenin function); (C) 8 
aripiprazole increases the expression of GABAA (containing β-1) receptors probably via 9 
PKA signalling; (D) aripiprazole elevates the phosphorylation of CREB1 via Akt-10 
GSK3β signalling and probably PKA signalling. 11 
Abbreviations: Akt = protein kinase B; CREB1 = cAMP-responsive element-binding 12 
protein 1; Dvl = dishevelled; GABA = γ-aminobutyric acid; GSK3β = glycogen 13 
synthase kinase 3-beta; PKA = protein kinase A. 14 
 15 
  16 
subsequent elevated phosphorylation levels of GSK3β, as well as up-regulation of the 17 
Dvl-GSK3β-β-catenin signalling pathway (Fig. 7-1B), which might contribute to the 18 
therapeutic effect of aripiprazole. In addition, by antagonising D2Rs, aripiprazole 19 
increases the expression of GABAA (containing β-1) receptors (Fig. 7-1C) probably via 20 
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activation of GSK3β and PKA (Fig. 7-1D). Since dysfunction of the NAc is linked to 1 
the positive symptoms of schizophrenia (Mikell et al., 2009), the current studies suggest 2 
that the suppression of GSK3β functions (increased phosphorylation), activation of Dvl-3 
GSK3β-β-catenin, increased expression of GABAA receptors and elevated activity of 4 
CREB1 in the NAc are very likely to be involved in the therapeutic effects of 5 
antipsychotics (probably on the positive symptoms of schizophrenia). 6 
 7 
7.2 Recommendations for further research 8 
The present studies have examined the effects of antipsychotics on various cellular 9 
signalling pathways in the brain regions related to the pathophysiology of schizophrenia. 10 
The results raised some important issues that need to be addressed. Suggested further 11 
studies are as follows. 12 
 13 
1. All of the current three antipsychotics have potent affinity for D2Rs, however, it is 14 
not clear whether these antipsychotics affected D2Rs solely to exert these effects. 15 
Therefore, further experiments are important to validate this issue, such as (1) using 16 
specific D2R antagonists (e.g. L-741,626 and raclopride) in combination with 17 
antipsychotics to treat animals, and (2) using imaging technique (e.g. PET) to 18 
investigate the binding properties of D2Rs in various brain regions.  19 
 20 
2. The transcription factor phosphorylation of relevant protein kinases (e.g. PKA, Akt, 21 
GSK3β and CREB1) are also required to be evaluated in the future studies. 22 
 23 
3. The present study (Chapter 4) suggests that antipsychotics might affect GABAA 24 
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PKA inhibitors (e.g. H-89 and KT-5720) may be used in the future studies to 1 
validate the role of PKA signalling in the actions of antipsychotics. 2 
 3 
4. The current studies have used three drugs with different pharmacological profiles. 4 
The comparisons between these drugs were performed by evaluating the bio-5 
markers only. Behavioural studies are required to validate whether these drugs are 6 
able to induce different behavioural changes corresponding to their 7 
pharmacological properties.  8 
 9 
5. Knockout animals (e.g. GSK3β knockout, CREB Ser133Ala knockout animals) 10 
might also be used to confirm the effects of antipsychotics on the relevant 11 
signalling pathways and behavioural changes. 12 
 13 
6. The current studies have employed only one dosage of aripiprazole. According to 14 
the FDA guidelines for clinical trials (FDA, 2005; Reagan-Shaw et al., 2008), a 15 
0.75 mg/kg/day aripiprazole dosage in rats is equivalent to ~7.5 mg/day in humans 16 
(60 kg body weight) based on body surface area. The effective dosage for 17 
aripiprazole to treat schizophrenia ranges from 10 to 30 mg/day (Di Sciascio and 18 
Riva, 2015). Therefore, whether other dosages of aripiprazole induce different 19 
cellular effects is worth further investigations. 20 
 21 
7. It is worth noting that aripiprazole has different effects from bifeprunox and 22 
haloperidol in the PFC and CPu. For example, acute administration of both 23 
aripiprazole and bifeprunox, but not haloperidol, increased GSK3β phosphorylation 24 
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PKA phosphorylation in the CPu, whereas haloperidol increased it (Chapter 4); 1 
moreover, 10-week administration of both aripiprazole and bifeprunox, but not 2 
haloperidol, elevated Akt and GSK3β phosphorylation in the PFC (Chapter 6). 3 
These different effects of aripiprazole could not be explained simply by its low 4 
intrinsic activity for D2Rs. Instead, these findings suggest that aripiprazole might 5 
have selective effects on the PKA and Akt-GSK3β signalling pathways in different 6 
brain regions. Since in vitro studies have demonstrated the functional selectivity of 7 
aripiprazole at D2Rs (Kikuchi et al., 1995; Koener et al., 2012; Shapiro et al., 2003; 8 
Urban et al., 2007), further studies (particularly in vivo studies) are necessary to 9 
investigate the mechanisms of functional selectivity of aripiprazole. For example, 10 
employing biosensors based on fluorescence and bioluminescence resonance 11 
energy transfer to monitor the conformation changes of relevant receptors induced 12 
by aripiprazole (Stallaert et al., 2011); using animal model to investigate the 13 
relationship between the functionally selective effects of aripiprazole and its unique 14 
therapeutic effects (Kenakin, 2011).  15 
 16 
8. Aripiprazole has partial agonism for 5-HT1A receptors and antagonism for 5-HT2A 17 
receptors, as well as affinity for many other receptors (e.g. 5-HT2C, H1 receptors) 18 
(Correll, 2010). It is unknown whether these receptors are involved in the effects on 19 
the signalling pathways and regulators examined in the present studies, and in the 20 
therapeutic actions of aripiprazole. Therefore, more specific studies are required to 21 
investigate the roles of these receptors in the actions of aripiprazole. 22 
 23 
9. Lastly, the studies included in this thesis have examined the effects of antipsychotic 24 
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neuronal changes in the brains (McCarley et al., 1999; McGuire et al., 2008; Wible 1 
et al., 2001; Zhuo et al., 2014), antipsychotics might act differentially and exert 2 
different effects in the diseased brains from the healthy ones. It is, therefore, 3 
necessary to investigate the effects of these drugs in the animal models for 4 
schizophrenia and other mental disorders in future studies. 5 
 6 
7.3 Conclusion 7 
The present studies have investigated the molecular mechanisms of aripiprazole on the 8 
PKA, Akt-GSK3β, Dvl-GSK3β-β-catenin signalling pathways, as well as GABAA 9 
receptors and CREB1. Aripiprazole, bifeprunox and haloperidol were injected in an 10 
acute study, and orally administered for three different time periods in short- and long-11 
term studies. The effects of these antipsychotics in the key brain regions that are related 12 
to the actions of antipsychotics have been examined. The results have provided in vivo 13 
evidence that aripiprazole has time- and brain regional-dependent effects on the PKA 14 
and Akt-GSK3β signalling pathways, as well as the relevant Dvl-GSK3β-β-catenin 15 
signalling, GABAA receptors and CREB1. These findings suggest that aripiprazole 16 
might exert its clinical effects via integrated effects of several signalling pathways and 17 
regulators.  18 
 19 
On the other hand, the present studies have found that aripiprazole and haloperidol, but 20 
not bifeprunox, had some similar effects on the Dvl-GSK3β-β-catenin signalling, 21 
GABAA receptors and CREB1 in the NAc, which suggests that aripiprazole and 22 
haloperidol might share common mechanisms in their actions at these signalling 23 
pathways and regulators. Therefore, by comparing aripiprazole with haloperidol, the 24 
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essential for aripiprazole to perform its functions, and for the development of other 1 
potential D2R partial agonists to achieve meaningful clinical effects.  2 
 3 
Last but not least, the long-term study has revealed the adaptive changes in Akt-GSK3β, 4 
Dvl-GSK3β-β-catenin signalling, GABAA receptors and CREB1 induced by chronic 5 
antipsychotic drugs administration. Since these pathways and regulators are closely 6 
associated with the pathophysiology of schizophrenia, these findings indicate that 7 
potential antipsychotics and treatments of schizophrenia may focus on these pathways 8 
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